CLINICAL STUDY PROTOCOL  
A PHASE 1, RANDOMIZED, PLACEBO -CON TR OLLED, 
DOSE -RANGING STUDY TO EV ALUATE THE SAFETY AND 
IMMUNOGENICITY OF V AL -181388 IN HEALTHY ADULTS IN A 
NON-ENDEMIC CHIKUNGUNYA REGION 
PROTOCOL NO. V AL -1813 88- P101  
Sponsor:  Moderna Therapeutics, Inc.  
200 Technology Square  
Cambridge, MA 021 39 
Sponsor Contact:  
 
Mod
erna Therapeutics  
500 Technology Square  
Cambridge,  MA 02139 
Telephone:  
IND No.  17166  
Version of Protocol:  4.0 
Date of Protocol:  30 August 2018  
CONFIDENTIAL  
The concepts and information contained in this document or generated during the study are 
considered proprietary and may not be disclosed in whole or in part without the expressed, 
written consent of Moderna Therapeutics, Inc. 
The study will be conducted according to the International Council for Harmonisation 
harmonised tripartite guideline E6(R1): Good Clinical Practice.  NCT #: NCT0332 5075
PPD
PPD
PPD
PPD
PPD
PPD
PPD
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 3 Investigator Protocol Agreement Page  
 
I agree to conduct the study as outlined in the protocol entitled “A Phase 1, Randomized, 
Placebo -Controlled, Dose -Ranging Study to Evaluate the Safety and Immunogenicity of 
VA L -181388 in Healthy Adults  in a Non-endemic Chikungunya Region ” in accordance with 
the guidelines and all applicable gov ernment regulations including US Title  21 of the Code of 
Federal Regulations Part  54. I have read and understand all sections of the protocol. 
   
Signature of Investigator   Date  
   
Printed Name of Investigator    
 
 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 4 Table of Contents  
Signature Page .......................................................................................................................... 2  
Investigator Protocol Agreement Page...................................................................................... 3  
Table of Contents ...................................................................................................................... 4  
List of Tables  ............................................................................................................................. 7  
List of Figures  ........................................................................................................................... 7  
Protocol Synopsis...................................................................................................................... 8  
List of Abbreviations ............................................................................................................... 21  
1 Introduction .................................................................................................................... 23  
1.1 Background ............................................................................................................23  
1.2 Nonclinical Studies in Development of VAL-181388 ...........................................26  
1.2.1  Nonclinical Efficacy  .................................................................................26  
1.2.2  Distribution  ...............................................................................................28  
1.2.3  Toxicology ................................................................................................30  
1.2.4  Genotoxicity .............................................................................................31  
1.3 Clinical Studies  ......................................................................................................33  
1.4 Rationale for Study ................................................................................................35  
1.5 Rationale for Dose Selection  .................................................................................35  
1.6 Rationale for Study Design  ....................................................................................36  
2 Study Objectives  ............................................................................................................. 37  
2.1 Primar y Objective  ..................................................................................................37  
2.2 Secondary Objectives .............................................................................................37  
2.3 Exploratory Objectives ..........................................................................................37  
3 Investigational Plan  ........................................................................................................ 38  
3.1 Study Design  ..........................................................................................................38  
3.2 Selection of Study Population ................................................................................44  
3.2.1  Inclusion Criteria  ......................................................................................44  
3.2.2  Exclusion Criteria  .....................................................................................45  
3.2.3  Subject Restrictions During the Study  ......................................................47  
3.3 Withdrawal of Subjects From the Study ................................................................48  
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 5 3.3.1  Reasons for Withdrawal  ............................................................................48  
3.3.2  Handling of Withdrawals  ..........................................................................50  
3.3.3  Replacements  ............................................................................................50  
3.4 Study Treatments  ...................................................................................................50  
3.4.1  Method of Assigning Subjects to Treatment Groups ................................50  
3.4.2  Treatments Administered  ..........................................................................51  
3.4.3  Management of Clinical Supplies  .............................................................54  
3.4.4  Blinding ....................................................................................................56  
3.4.5  Breaking the Blind  ....................................................................................57  
3.4.6  Treatment Compliance  ..............................................................................57  
3.4.7  Prior and Concomitant Medications .........................................................58  
3.5 Study Procedures  ...................................................................................................59  
3.5.1  Safety Contact  ...........................................................................................60  
3.5.2  Completion of Memory Aid  ......................................................................61  
3.5.3  Immunogenicity Assessments  ...................................................................61  
3.5.4  Total Blood V olume  ..................................................................................62  
3.5.5  Safety Assessments  ...................................................................................62  
3.5.6  Solicited Safety Measurements  .................................................................63  
3.5.7  Unsolicited Safety Measurements  ............................................................65  
3.5.8  Clinical Laboratory Testing  ......................................................................70  
3.5.9  Vital Sign Measurements  ..........................................................................72  
3.5.10  Physical Examinations  ..............................................................................73  
3.6 Statistical Analysis Plans  .......................................................................................73  
3.6.1  Safety Endpoints  .......................................................................................73  
3.6.2  Immunogenicity Endpoints .......................................................................74  
3.6.3  Sample Size Calculations  .........................................................................74  
3.6.4  Analysis Sets  .............................................................................................75  
3.6.5  Statistical Analysis  ....................................................................................75  
3.6.6  Handling of Missing Data .........................................................................77  
3.6.7  Interim Analyses  .......................................................................................77  
3.7 Data Quality Assurance ..........................................................................................78  
4 Investigator Obligations ................................................................................................. 79  
4.1 Confidentiality  .......................................................................................................79  
4.2 Institutional Review  ...............................................................................................79  
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 6 4.3 Subject Consent .....................................................................................................80  
4.4 Study Reporting Requirements ..............................................................................80  
4.5 Financial Disclosure and Obligations ....................................................................80  
4.6 Investigator Documentation ...................................................................................81  
4.7 Study Conduct ........................................................................................................82  
4.8 Data Collection  ......................................................................................................82  
4.8.1  Case Report Forms and Source Documents .............................................82  
4.9 Adherence to Protocol............................................................................................82  
4.10  Reporting Adverse Events ......................................................................................83  
4.11  Investigator’ s Final Report  ....................................................................................83  
4.12  Records Retention  ..................................................................................................83  
4.13  Publications ............................................................................................................83  
5 Study Management ......................................................................................................... 84  
5.1 Monitoring .............................................................................................................84  
5.1.1  Monitoring of the Study............................................................................84  
5.1.2  Inspection of Records ...............................................................................84  
5.2 Management of Protocol Amendments and Deviations.........................................84  
5.2.1  Modification of the Protocol .....................................................................84  
5.2.2  Protocol Violations and Deviations ..........................................................85  
5.3 Study Termination  ..................................................................................................85  
5.4 Final Report ...........................................................................................................86  
6 Appendices ..................................................................................................................... 87  
6.1 Appendix 1: Schedule of Events ............................................................................87  
6.2 Appendix 2: Adverse Events of Special Interest ....................................................93  
6.3 Appendix 3: Toxicity Grading Scale Tables ..........................................................97  
7 Reference List  ............................................................................................................... 103  
 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 7 List of Tables  
Table 3 -1 Part A: Overview of Visits  .............................................................................. 42  
Table  3-2  Part B: Overview of Visits  .............................................................................. 43  
Table  3-3  Total Blood V olume  ........................................................................................ 62  
Table  6-1  Part A Schedule of Events  ............................................................................... 88  
Table  6-2  Part B Schedule of Events ............................................................................... 92  
Table  6-3  Tables for Clinical Abnormalities  ................................................................... 97  
Table  6-4  Tables for Laboratory Abnormalities  ............................................................ 100  
List of Figures  
Figure  1-1  Chikungunya Virus Genome and Post-Translational Processing of Structural 
Proteins ........................................................................................................... 24  
Figure  1-2  Structure of Alphavirus Virion ........................................................................ 25  
Figure 3 -1 Dose Level Schematic ..................................................................................... 42  
 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 8 Protocol Synopsis  
Protocol 
Number:  VA L -181388 -P101  
Title:  A Phase 1, Randomized, Placebo- Controlled, Dose -Ranging Study to 
Evaluate the Safety and Immunogenicity of V AL -181388 in Healthy 
Adults in a Non -endemic Chikungunya Region  
Study Phase:  1 
Study Site:  One site in the United States  
Objectives:  Primary:  
• To assess the safety of VAL -181388 relative to placebo. 
Secondary:  
• To determine the immunogenicity of 3 dose levels o f  VA L -181388 
to inform the choice  of dose for further development of this vaccine. 
Immunogenicity assessment will be based on cha nges from baseline 
in the following: 
o Serum neutralizing antibody titers  to chikungunya virus 
(CHIKV)  
o Serum binding antibody titers to CHIKV- specific proteins 
Exploratory: 
• To assess the cross -reactivity of serum antibodies to related viruses, 
including alphaviruses and  flaviviruses 
• To explore other  assays to characterize the immune response to  
CHIKV 
Study Design 
and 
Methodology: This is a Phase 1, first -in-human, randomized, observer -blind ed, 
placebo -controlled, dose escalation study to evaluate the safety and 
immunogenicity of  3 dose levels of  VA L -181388 in healthy adult 
subjects (18 to 49 years  of age, inclusive ). VA L -181388 is a messenger 
RNA ( mRNA)- based vaccine being developed  for prevention of disease 
associated with CHIKV infection . 
Chikungunya virus is a positive -sense, single -stranded  RNA virus, of the 
alphavirus family, in the genus of the togavirus family. It can cause 
disease in humans and other mammals. It is an arbovir us that is 
transmitted by  a mosquito vector ( Aedes spp). Currently there is no 
approved vaccine to protect against this disease, which has recently 
spread through tropical regions. 
This is a 2-part study, with Part A including  dose escalation and safety 
and immune testing through 28 days following the final vaccination. 
Once subjects complete Part A they will transition  to Part B. Part B is a 
conti nued safety follow -up through 12 months  and an assessment of 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 9 immunogenicity and immune persistence  at approximately 6 and 
12 months after final vaccination.  
Part A  
In Part A,  sequential dose escalation o f  VA L -181388 is planned in 3 dose 
level cohorts ( 25, 50, and 100 µg ) with each subject receiving 
2 vaccinations separated by 28 days . Subjects will be r andom ly assigned  
to receive either V AL -181388 or placebo.  
For each cohort, a sentinel safety group of 4 subjects will be enrolled 
who will be random ly assigned  to VA L -181388 or placebo (3:1) and 
followed for 7 days after the first vaccination  with review of 
reactogenicity and safety laboratory results prior to randomizing the 
remainder of the cohort. An internal safety team (IST) will oversee the 
safety of the trial and will review blinded safety data during Part A of the study to ensure adherence to the protocol, monitor safety laboratory test results and reactogenicity, and raise concerns to the Safety Monitoring 
Committee (SMC) should there be safety issues or operational 
challenges that could affect subject safety. Only after review by the IST 
of the blinded safety data (reactogenicity, safety lab oratory result s, and 
adverse events [ AEs]) through 7 days after the first vaccination of the 
sentinel safety lead -in for each cohort planned, will approval be given to 
allow randomization of the remainder of that cohort. The SMC will 
approve escalation to the next higher dosing cohort after review of 
blinded safety data of the currently dosed cohort through 7 days 
following the second vaccination and any cumulative safety data of all cohorts as the trial advances. The SMC will also be convened (ad  hoc 
meeting) if a pause rule is triggered.  
Dose Level Cohort Assignments : VA L -181388 (or placebo)  
administered IM at Visit 1 and a second dose adminis tered 28 days later  
(Visit 4). 
Cohort 1 ( N = 20): 25 µ g  VA L -181388 or placebo (ratio = 3:1) 
Cohort 2 ( N = 20): 50 µ g  VA L -181388 or placebo (ratio = 3:1) 
Cohort 3 ( N = 20): 100 µ g VA L -181388 or placebo (ratio = 3:1) 
VAL-181388 Administration and Dose Escalation Schema 
 

Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 10 VA L -181388 (or placebo) will be administered as an intramuscular (IM) 
injection (0.5 mL) into the deltoid muscle , preferably in the 
non-dominant arm, as a 2-dose schedule; the first dose will be given at 
Visit 1  followed by a second dose 28 days later. V AL -181388 
accountability, dose preparation, and administration will be performed 
by unblinded pharmacy personnel or unblinded designees who will not 
participate in any other aspect of the study. The remainder of t he site staff 
and all subjects will remain blinded to treatment assignment.  
Consent and S creening will occur over a 28-day period prior to 
randomization. A total of 20 subjects will be randomly assigned to each 
dose level cohort, 4 subjects (3 VAL -181388 and 1 placebo) to the 
sentinel safety group and 16 subjects (12 V AL -181388 and 4 placebo) to 
the expansion group, resulting in 15 subjects being randomly assigned to VA L -181388 and 5 
subjects being randomly assigned to placebo 
(3:1 ratio overall). Subjects meeting all eligibility  criteria will receive the 
first vaccination at  Visit 1. Each subject will be monitored in the clinic 
for at least 1 hour following each vaccination for safety. Assessments 
will include vital sign measurements and any immediate reactogenicity.  
Of note, on the day of scheduled vaccination, if a subject is noted to have 
a systolic or diastolic blood pressure, heart rate , or respiratory rate 
measurement  that shows Grade 2 or higher  toxicity  after 2 measurements 
(even after relaxing or resting) ; has an acute illness ; or has an oral 
temperature >38°C , the subject should not receive a  vaccination on that 
day and will need to return on subsequent days for their vaccination. 
All subjects will return to the clinic at 7  (+3), 17 (±3), and 28 (+7) days 
following each vaccination. In addition, the  sentinel safety group will 
return to the clinic at 1 , 2, and 21 (+3)  days following the first 
vaccination. A second vaccination will occur 28 days after the first 
vaccination (+7  days).  
Subjects will be instructed on recording solicited (local and systemic 
reactogenicity  events ) and unsolicited AEs, temperature,  and 
medications (prescription or over -the- counter) on their memory aid 
(ie, diary  card). Subjects will also be asked to call/ret urn to the clinic 
within 24 hours if reactogenicity  reaches Grade 3 or higher during the 
first 7 days following vaccination. As standard practice, a reminder call 
will be made to the subject by the site at least once during the first 7  days 
following each vaccination to answer any questions and ensure that the memory aid is being completed correctly  and consistently.  
Safety assessments will include toxicity grading of solicited (local and systemic reactogenicity  events ) and unsolicited AEs
, vital sign 
measurements, physical examination findings, and clinical laboratory 
test results  for hematology, serum chemistry, coagulation, and urinalysis. 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 11 All unsolicited AEs will be collected and additional specific categories 
will include serious adver se events (SAEs); AEs of special interest 
(AESIs) ; and medically attended AEs . Subjects will self -report (using a 
memory aid) solicited (local and systemic reactogenicity events) and 
unsolicited AEs  and medication usage (over -the- counter and 
prescription) through 28  days after each vaccination.  In addition, 
subjects will be instructed  to measure their oral temperature daily for the 
first 7  days post vaccination and record that measure on the memory aid.  
At applicable clinic visits, the investigator will rev iew the entries on the 
memory aid with the subject to ensure consistency. 
Safety laboratory tests will be performed at Screening, on vaccination 
days (before dosing ), and at 7 (+3) days after each vaccination. At  
17 (±3) days f ollowing each vaccination and at  28 (+7) days after the 
second vaccination , safety laboratory tests will be performed for 
coagulation and liver function tests only . The sentinel safety group will 
also have coagulation and liver function tests collected at 21 (+3) days 
after the fi rst vaccination . Additional safety laboratory tests may be 
conducted at any time by the investigator  if deemed necessary.  
Blood samples for immunogenicity will be collected on dosing days 
(pre-dose) and at 28 (+7 ) days after the final vaccination.  
Subjects unable to complete their second vaccination due to 
noncompliance with the visit schedule and not due to a cohort pause will 
still be required to follow the original visit and testing schedule. 
Specifically, these subjects will be asked to undergo blood collection to 
comply with a second immune test at 56 (+10) days (Visit 7) following 
the first vaccination.  
To allow cohort advancement, the following data from the highest dosed cohort are expected to be reviewed by the SMC: 1)  toxicity scoring of 
safety laboratory test results through 7 
days following the second 
vaccination (through Visit  5); 2) toxicity scoring of vital signs and 
reactogenicity through 7 days following the first and second vaccination (through Visit  5); 3)  all unsolicited AEs (with g rading and attribution). 
Data will be prepared by dose cohort  
and timing relative to each 
vaccination. As safety data on all cohorts accumulate, the SMC also 
review ongoing AEs as well as cumulative safety laboratory test results, reactogenicity, and AEs across vaccine doses for subjects remaining in Part 
A of the study, thereby providing a cumulative and comprehensive 
review of safety. Should a cohort pause occur due to pre -specified 
criteria, the SMC will be convened for an unscheduled (ad hoc) meeting and be provided with specific safety data related to the trigger of the 
pause.   
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 12 Part A is concluded for each subject when they return to the clinic for 
Visit 7 (28 days after final vaccination ). At that time, subject s will 
transition to Part B of the study. 
 Part A: Overview of Visits 
Study visit  0 1 1aa 1ba 2 3 3aa 4 5 6 7 
Vaccination day   X      X    
Days relative to most 
recent vaccination  NA 0 1 2 7 17 21 28 7 17 28 
Window allowance  +28 0 0 0 +3 ±3 +3 +7 +3 ±3 +7 
Screening  X           
Physical examinationb X Xc   X  X Xc X  X 
Safety laboratory tests  X Xc   X X X Xc X X X 
Vital sign measurements  X Xd X X X  X Xd X  X 
Immune laboratory tests   Xc      Xc   X 
Study drug 
administratione  X      X    
Review of concomitant 
medications  X X X X X X X X X X X 
Review of safety 
(solicited and 
unsolicited)   Xd X X X X X Xd X X X 
a. Applies to sentinel safety group  only.  
b. Symptom- directed  after Screening . 
c. Obtained before study drug administration . 
d. Obtained before and after study drug administration . 
e. Vaccination  cannot occur if systolic or diastolic blood pressure, heart rate, or 
respiratory rate measurements show  Grade 2 o r higher toxicity after 
2 measurements; if a s ubject has an acute illness; or if a subject has an oral 
temperature >38°C . 
 Part B  
To monitor for longer- term safety and immune persistence, each subject 
will be entered into a continued blinded follow -up period (Part  B). This 
period will be conducted such that subjects and safety monitors will 
remain blinded to treatment assignment. Par t B of the study is initiated 
for a subject once they have returned for Visit  7 (28 days following the 
second vaccination).  
Once entered into Part  B, each safety contact will occur by telemedicine 
(eg, telephone, text  message, internet) every 28 (±7) days, and blood 
samples for immune persistence will be collected from each subject on 
Visit 1 2 (±15  days) and Visit 19 (+15 days). Each safety contact will 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 13 capture outcomes of any AESI or SAE that remains unresolved since the 
last visit or is newly identified through scripted query.  
The telemedicine visits may require additional data through medically 
attended visits, in addition to medications and vaccinations taken by the 
subject during this time. Subjects will have consented during study 
enrollmen t to allow access to additional medical records needed to 
complete Part B, thereby allowing the blinding of the treatment 
assignment to be maintained. 
Part B:  Overview of Visit s  
Study visit 8 9 10 11 12 13 14 15 16 17 18 19 
Study day from 1st 
dose if 2nd dose not 
completed  84 112 140 168 196 224 252 280 308 336 364 392 
Study day from 2nd 
dose, if completed  56 84 112 140 168 196 224 252 280 308 336 364 
Window allowance  ±7 ±7 ±7 ±7 ±15 ±7 ±7 ±7 ±7 ±7 ±7 +15 
Safety contact  X X X X  X X X X X X  
Immune samples      X       X 
Serious adverse 
events  X X X X X X X X X X X X 
Adverse events of 
special interest  X X X X X X X X X X X X 
End of Study            X 
When all subjects have completed their final contact ( approximately 
12 months after their last vaccination), immune testing is completed , and 
all queries resolved , the database will be locked and analyzed and a final 
clinical study report will be provided to regulators. 
Inclusion 
criteria:  Each subject must meet all of the following criteria during the screening 
period to be enrolled in this study: 
1. The subject is male or female between 18 and 49 years of age, 
inclusive. 
2. The subject has a body mass index between 18 and 35 kg/m2, 
inclusive. 
3. The subject is considered by the investigator to be in good general 
health as determined by medical history, clinical laboratory 
assessments, vital sign measurements, and physical examination 
findings at Screening . 
4. Female subjects must be non -pregnant and non- lactating and meet  
one of the following criteria : A) post -menopausal (defined as 
amenorrhea for 12  consecutive months without an alternative 
medical cause or documented serum  follicle -stimulating hormone 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 14 level in the post -menopausal range); B) surgically  sterile (ie, 
hysterectomy, bilateral tubal ligation, or bilateral oophorectomy). 
NOTE: procedures and laboratory results must be confirmed in the 
medical record, by physical examination, or by official written 
confirmation of a procedure ; or C) if of chil dbearing potential, agrees 
to be heterosexually inactive from at least 21  days prior to enrollment 
and through 3 months after the final vaccination or  agrees to 
consistently use any  of the following methods of contraception from 
at least 21 days prior to enrollment and through 3 months after the 
final vaccination : condoms (male or female) with spermicide, 
diaphragm with spermicide, cervical cap with spermicide, 
intrauterine device, oral or patch contraceptives, Norplant®, 
Depo -Provera®, or other Food and Dr ug Administration -approved 
contraceptive method which is designed to protect against pregnancy . 
Periodic abstinence (eg, calendar, ovulation, symptothermal, 
post-ovulation methods) and withdrawal are not acceptable methods 
of contraception. 
5. Male subjects must agree to consistently use appropriate 
contraception and to refrain from sperm donation through 3 months after the final vaccination.  
6. The subject understands and agrees to comply with the study 
procedures and provides written informed cons ent before an y study 
procedures are performed.  
7. The subject has access to a consistent and reliable means of telephone contact, which may be in the home, workplace, or by personal mobile electronic device.  
8. The subject agrees to stay in contact with the study site for the 
duration of the study, to provide updated contact information as 
necessary, and has no current plans to move from the study area for 
the duration of the study.  
Exclusion 
criteria:  Subjects meeting any of the following criteria will be excluded from t he 
study:  
1. The subject has any ongoing significant  chronic illness requiring 
medical or surgical care. A symptomatic conditions or findings (eg, 
mild hypertension, dyslipidemia) that are not associated with 
evidence of end -organ damage are not exclusionary p rovided that 
they are being appropriately managed and are clinically stable  in the 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 15 opinion of the investigator  (ie, unlikely to result in symptomatic 
illness within the time -course of this study).  
2. The subject is a female of childbearing potential and has a positive 
pregnancy test at Screening or on the day of vaccination. 
3. The subject has any abnormal screening laboratory result meeting the 
criteria  listed below . 
a. Elevated l iver function tests (aspartate aminotransferase, 
alanine aminotransferase, total or direct bilirubin , or alkaline 
phosphatase ), elevated creatinine , or reduced  platelet s with a 
toxicity score ≥ Grade 1 at Screening . Re-testing of these 
parameters  is not allowed. 
b. Other than a)  above, any safety laboratory test result (urine or 
serum) w ith:  
i. a toxicity score ≥ Grade 2   
ii. a toxicity score of ≥ Grade 1 deemed clinically 
significant  
4. The subject has participated in another investigational study 
involving any investigational product (ie, study drug, biologic, 
device) within 60 days, or 5 half -lives, whichever is longer, before 
planned date of first vaccination. 
5. The subject has received any live attenuated or inactive vaccines 
within 4  weeks prior to enrollment , or plans to receive any vaccine 
during the active vaccination period (through 4 weeks after their last 
planned vaccination).  
6. The subject has received (at any time) a vaccine for CHIKV , dengue, Yellow Fever, tick -borne encephalitis, or Japanese encephalit is. 
7. The subject has a history of confirmed or suspected CHIKV 
infection , has lived in a CHIKV -endemic area for >1 year , or has 
cumulatively spent more than 30 days in a CHIKV -endemic area 
within the last 5 years . 
8. The subject has reported previously partici pating in an 
investigational study involving lipid nanoparticles. 
9. The subject has a history of hypersensitivity or serious reactions 
(eg, anaphylaxis, urticaria, other significant reaction) to previous 
vaccinations.  
10. The subject has any known or suspected a utoimmune disease or 
immunosuppressive condition, acquired or congenital, as determined by medical history and/or physical examination.  
11. The subject has a history of arthritis (including inflammatory 
arthritis ) or arthralgia . 
12. The subject has a neurologic di sorder (eg, history of seizures, 
Guillain -Barre syndrome, dementia, vasculitis, or any known 
congenital or acquired disorder).  
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 16 13. The subject received immunoglobulins and/or any blood products 
within the 3 months preceding the administration of the study drug 
or plans to receive such products at any time during the study.  
14. The s ubject has had chronic administration (defined as more than 
14 continuous days) of an immunosuppressant or other 
immune -modifying drug within 6 months prior to vaccine  
administration  or plans to receive any products during the active 
vaccination period (through 4 weeks after their last planned 
vaccination) . An immunosuppressant dose of a glucocorticoid will be 
defined as a systemic dose of ≥10 mg of prednisone per day or 
equivalent. The use of topical, inhaled, and nasal glucocorticoids will be permitted.  
15. The subject is currently receiving antipyretic or analgesic medication on a daily or every other day basis (a daily dose of ≤100 mg of aspirin 
given under the guidance of a physician is not a contraindication to 
enrollment).  
16. The subject has any acute illness at the time of enrollment (defined 
as the presence of a moderate or severe illness with or without fever, or an oral temperature >38.0°C on the planned day of vaccination ). 
In such cases, subjects may be re -
evaluated during the screening 
period for resolution of the illness  to allow  at least 3 days of wellness 
prior to the planned vaccination. 
17. The subject has any significant disorder of coagulation (acquired or 
hereditary)  requiring on going or intermittent treatment. Subjects 
receiving prophylactic an tiplatelet medications, eg, low -dose 
acetylsalicylic acid (≤100 mg/day or equi valent), and without 
clinically apparent bleeding tendency, are eligible.  
18. The subject has a history of idiopathic urticaria.  
19. The subject has a history of alcohol abuse or drug addiction within 1 year before the planned day of dose administration (self-reported). 
20. The subject has a positive  test result for drugs of abuse at Screening.  
21. The subject has any abnormality or permanent body art (eg,  tattoo) 
that would obstruct the ability to observe local reactions at the 
injection site (deltoid region).  
22. The subject has any condition that, in the opinion of the investigator, would pose a health risk to the subject if enrolled or could interfere with evaluation of the study drug or interpretation of study results 
(including neurologic or psychiatric conditions deemed likely to 
impair the quality of safety reporting). 
23. The subject has a positive test result for hepatitis B surfa ce antigen, 
hepatitis C virus antibody, or human immunodeficiency virus types  1 
or 2 antibodies.  
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 17 24. The subject has a history of active cancer (malignancy) in the last 
10 years. An exception is a subject with adequately treated 
nonmelanomatous skin carcinoma, who may participate in the study.  
25. The subject has donated blood or blood products >450 mL within 
30 days of dosing. 
26. The subject has any screening vital sign measuremen t (systolic or 
diastolic blood pressure, heart rate , or respiratory rate) that shows 
greater than or equal to Grade 2 toxicity  after 2 measurements.   
27. The subject is an employee or first-degree  relative of the Sponsor , 
PPD, or study site personnel. 
 
Part A Safety 
Assessments:  • Solicited AEs (local and systemic reactogenicity events) collected for 
7 days following each vaccination with toxicity grading. 
• Unsolicited AEs collected for 28 days following each vaccination. Additional classification if serious, medically attended , or a n AESI.  
• Safety laboratory test results  (serum chemistry, hematology, 
coagulation, and urinalysis) with toxicity grading 
• Vital sign measurements with toxicity grading and physical 
examination findings  
Part B Safety Assessments  • Serious AEs  and AESIs through 1 year  (or until resolved , whichever 
comes first ) following the last vaccination   
Part A Immunogenicity Testing : • Neutralizing serum antibody titers to CHIKV ( baseline and 28  days 
after each vaccination )  
• Serum binding  antibody titers ( immunoglobulin G [ IgG]) to 
CHIKV -specific proteins ( baseline and 28 days after each 
vaccination ) 
• Exploratory antibody assay s may be performed with excess serum  to 
assess for cross- reactivity to related viruses at the discretion of the 
Sponsor 
• Additional ex ploratory assays based upon current research may be 
performed  with excess serum  to better characterize the immune 
response to the CHIKV proteins at the discretion of the Sponsor 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 18 Part B 
Immunogenicit
y Testing:  • Neutralizing serum antibody titers to CHIKV ( at 6 and 12 months  
after the last vaccination)  
• Serum binding antibody titers ( IgG) to CHIKV -specific proteins (at 
6 and 12 months after the last vaccination)  
• Exploratory antibody assay s may be performed with excess serum  to 
assess for cross- reactivity to related viruses at the discretion of the 
Sponsor  
• Additional exploratory assays based upon current research may be 
performed with excess serum to better characterize the immune 
response to the CHIKV proteins at the discretion of the Sponsor 
Study Drug, 
Dosage, and 
Route of Administration  25, 50, or 100  µg VAL -181388 or placebo (0.9% Sodium Chloride 
Injection, USP) will be prepared as outlined in the pharmacy manual and 
administered via IM injection (0.5 mL) into the deltoid muscle on 
designated vaccination days, preferably in the non-dominant arm. 
Samp le Size:  Approximately 60 subjects are planned to be randomized, 20 per dose 
level . Formal sample size calculations were not performed  as this is an 
observational safety and immunogenicity study with no formal null 
hypotheses being tested.  
Statistical Methods:  Safety : Data for subjects receiving placebo will be pooled across all dose 
levels for all presentations . Reactogenicity will be summarized by dose 
level s (25, 50, or 100 µg or placebo), vaccination (first or second), 
duration, relationship to study vaccine, and severity. Adverse events will 
be coded by preferred term and system organ class using the Medical 
Dictionary of Regulatory Activities  and summarized by part, treatment, 
vaccination (first or second), and overall. Adverse events will also be 
summarized by severity and relationship to study vaccine. Descriptive statistics will be presented and the difference in the proportion of AEs 
will be provided comparing each dose level with placebo recipients 
pooled across all dose levels . Adverse events for s ubjects in the safety 
cohort for each dose level will be provided in a separate subject listing. Adverse events leading to withdrawal, AESIs, medically attended AEs, 
and SAEs will be provided by subject in a listing.  
Safety data f rom clinical laboratory test results  and vital sign 
measurements will be graded by severity and analyzed by treatment 
group and vaccination (first or second). Absolute and change from 
baseline values will be provided according to the toxicity table, along with mean, median, and standard deviation. Results of hematology, 
serum chemistry, coagulation, and urinalysis assessments; 
urine drug 
screen ; and pregnancy testing will be listed for all subjects randomly 
assigned to receive study treatment.  
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 19 Medical histo ry data for all subjects randomly assigned to receive study 
treatment will be presented by subject in a listing.  
Baseline demographic and background variables will be summarized by 
treatment group and cohort for all subjects. The number of subjects who enr
oll in the study and the number and percentage of subjects who 
complete the study will be presented. Frequency and percentage of 
subjects who withdraw or discontinue from the study, and the reason for withdrawal or discontinuation, will also be summarized.  
Prior and concomitant medication will be listed (with start and stop 
dates) for each subject and summarized by common medical dictionary coding. Any vaccinations that occur during the trial conduct will also be captured and summarized . 
Immunogenicity : The following immunogenicity outcome measures 
(for serum  neutralizing antibody titers and serum  binding antibody titers 
to CHIKV -specific proteins) and their 95%  confidence intervals, where 
appropriate, will be summarized by dose level cohort and combined 
placebo, and by days post- vaccination : 
• Geometric mean titer (GMT) at baseline (pre -vaccination  at Visit 1) 
and at  post-dose time points   
• Geometric mean ratio Post/Pre : the ratio of post -vaccination GMT to 
pre-vaccination ( Visit 1) GMT of subjects who have a baseline 
sample and post-vaccination results at post-dose time points   
• Seroresponse : The proportion of subjects in each treatment group 
who either had an undetectable titer at baseline and detectable titer after vaccination, or detectable titer at baseline and at least a 4 -fold 
increase (of baseline titer) after vaccination will be calculated.   
Following completion of each dose level cohort in Part A, the database 
will be locked for that cohort and safety and/or immune testing results 
through 28 days following the final vaccination will be analyzed. As dose 
escalation occurs, cumulative analyses will be included for each 
subsequent data lock to allow for all prior dos e level  cohorts to be 
analyzed by  dose level  and in aggregate for VAL -181388 exposure. 
Imm unogenicity and safety data, including mean group analyses of 
change from baseline, where applicable, will be summarized for each 
dose level  cohort and combined placebo group. These analyses will be 
performed by an unblinded team, independent of the study team. All 
study personnel and participants other than the third -party  statistician 
will remain blinded to treatment allocation. These data will be provided to designated S
ponsor representatives only. They will inform decisions 
on this and other development  programs using the same mRNA platform. 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 20 Data may be unblinded to the Sponsor and dosing adjustments may be 
made during the conduct of the study should the data reveal the need to 
adjust dosing due to either safety or immune response.  
An interim analysis o f safety, reactogenicity , and immunogenicity data 
collected from Day 1 to Month 7 will be conducted and will be reported 
on a treatment assignment level. Access to i ndividual listings will be 
restricted  to identified Sponsor members and the clinical research 
organization unblinded statistician. Study sites will remain blinded. This 
analysis will provide information regarding short -term antibody 
persistence.  
The final analysis of safety and immunogenicity data collected from Visit 
Day 1  through the end of the study will be performed as soon as data are 
cleaned and locked. The results of this analysis will be presented in a 
clinical study report including i ndividual data listings . 
 
Additional information can be found in the statistical analysis plan. 
Date of 
Protocol: 30 August 2018 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 21 List of Abbreviations  
 
Abbreviation  Definition  
AE adverse event  
AESI  adverse event of special interest  
CARPA  complement activation -related pseudoallergy  
CBER  Center for Biologics Evaluation and Research  
CFR  Code of Federal Regulations  
CHIKV chikungunya virus 
DAIDS  Division of AIDS  
eCRF  electronic case report form  
ECSA  East Central South African  
EOS  end-of-study 
FDA  Food and Drug Administration 
GMT  geometric mean titer  
HA hemagglutinin  
IB investigator ’s brochure  
ICF informed consent form 
ICH International Council for Harmonisation  
ID intradermal  
IFN interferon  
IgG immunoglobulin G  
IM intramuscular  
IRB institutional review board  
IST internal safety team  
IV intravenous  
LLOQ  lower limit of quantification  
LNP  lipid nanoparticle 
MedDRA  Medical Dictionary for Regulatory Activities  
mRNA messenger RNA  
MTD  maximum tolerated dose  
NOAEL  no observed adverse effect level  
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 22 Abbreviation  Definition  
ORF  open reading frames  
SAE  serious adverse event  
SMC  Safety Monitoring Committee  
ULOQ  upper limit of quantification  
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 23 1 Introduction  
1.1 Background  
Chikungunya virus (CHIKV) is a mosquito -borne alphavirus posing a significant public health 
problem in tropical and subtropical regions . While chikungunya has been present in Africa for 
centuries, it has recently caused outbreaks and epidemics in new regions reflecting  the 
increasing distribution of the Aedes  mosquito. A chikungunya epidemic beginning in 2004 in 
Kenya, which spread  to the Indian Ocean islands and to India, and was exported to nearly all 
regions of the world via infected travelers, resulted in millions of infected individuals and 
brought chikungunya to the attention of the western world. As of April 2016, chikungunya  
cases had been reported in 103 countries and territories around the world, including 
46 countries and territories throughout the Americas  (Center s for Disease Control and 
Prevention 2016). There are an estimated 3 million cases of chikungunya globally. 
Chikungunya virus infection causes chikungunya, characterized by an acute onset of fever, 
rash, myalgia, and debilitating polyarthralgia ( Schwartz and Albert 2010; Weaver et al 2012 ), 
from which it derives its name which means “that which bends up” when tran slated from 
Makonde (language spoken by an ethnic group in southeast Tanzania and northern 
Mozambique) ( Halstead  2015). It is rarely fatal, but neurological sequelae such as 
Guillain -Barre syndrome and chronic arthritides have been increasingly recognized. 
Since its identification in 1952 ( Robinson 1955), CHIKV isolates from around the world have 
been grouped into three broad genotypes which correspond to geographic origin: (1)  Asian, 
(2) West African, and (3) East Central South African (ECSA) ( Weaver et al  2012). Isolates 
from the Indian Ocean region since 2000 are closely related to the ECSA lineage, and many 
harbor mutations that augment replication and transmission in Aedes albopictus  mosquitos 
(Tsetsarkin et al 2011 ; Weaver et al 2012 ). The Aedes aegypti  mosquito is the classical vector 
for CHIKV and is widely distributed across equatorial countries, and the jump to Aedes albopictus  puts additional regions such as the United States and Europe at risk, as this 
species is found in these more temperate climates and is considered a strong viral vector for 
spread of disease ( Weaver and Lecuit 2015).  
Chikungunya virus is an alphavirus of t he Togaviridae  family with a positive -strand RNA 
genome of 11.8 kilobases. Like other alphaviruses, the genome is capped and polyadenylated, 
and encodes 2 open reading frames (ORFs). The 5´ ORF (2/3 of the genome) encodes 4 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 24 nonstructural proteins required for viral replication and the 3 ´ ORF encodes the structural 
proteins. The structural proteins are expressed as a single polyprotein from a subgenomic 
promoter and are cleaved by viral and cellular proteases into capsid (C) and envelope glycoproteins E3, E2, 6K, and E1 ( Figure  1-1) ( Kuhn 2007). The mature chikungunya virion 
is 70 nm in diameter and contains 240 heterodimers of E1/E2 arranged as 80 trimer ic spikes 
on its surface ( Figure  1-2) (Strauss JH and Strauss EG 1994; Zhang et al 201 1). The E1 protein 
serves as the fusion protein and the E2 as the attachment protein.  
Figure  1-1 Chikungunya Virus  Genome and Post-Translational Processing of 
Structural Proteins  
 
 
Top panel: Organization of the CHIKV  genome, including structural and nonstructural pol yproteins and 
26S subgenomic promoter ( Weaver et al 2012 ). Bottom panel: Threading of the chikungunya virus  structural 
polyprotein through the endoplasmic reticulum and processing by proteases ( Li et al 2010 ).  
 

Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 25 Figure  1-2 Structure of Alphavirus Virion 
 
Abbreviation: CP, capsid protein.  
Cryo -electron microscopic reconstruction of the alphavirus virion ( Zhang et al 201 1, Weaver et al 2012 ).  
 
Although the detailed mechanism of protection against CHIKV infection in humans is not 
completely understood, it is clear that neutralizing antibodies play an important role ( Couderc 
et al 2009). Natural CHIKV infection of humans induces high neutralizing antibody titers 
(Lanciotti et al 2007) and immunoglobulin G  (IgG)  levels correlate with viral clearance and 
protection ( Kam et al 2012a , Kam et al 2012b ). Human CHIKV -specific neutralizing 
monoclonal antibodies have also been isolated and shown to protect animals from experimental CHIKV infection ( Smith et al 2015). The majority of these monoclonals recognize the 
E2 protein and are able to cross -neutralize CHIKV from all genotypes, including currently 
circulating ECSA strains ( Smith et al 201 5). Passive immunotherapy of convalescent sera has 
also been shown to protect animals from CHIKV infection ( Partidos et  al 2011 ). 

Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 26 Further details on messenger RNA ( mRNA)- based therapeutics, as well as the physical, 
chemical, and pharmaceutical properties of V AL -181388 can be found in the investigator ’s 
brochure (IB).  
1.2 Nonclinical Studies in Development of V AL -181388 
1.2.1 Nonclinical Efficacy  
The species selected for nonclinical studies to demonstrate efficacy and safety of VAL -181388 
are mice and rats. Mice are susceptible to CHIKV disease in the first few weeks of lif e, but 
adult wild -type mice are resistant ( Couderc et al 2008), which makes testing of prophylactic 
vaccines challenging. Adult inbred mice with a partial or complete defect in the interferon 
(IFN) pathway are widely used as animal models for CHIKV research. Inoculation of these 
strains with CHIKV results in high levels of viremia and nearly systemic virus dissemination 
to other tissues, with high viral loads ( Couderc et al 2008; Partidos et al 2011 ; Gardner et al 
2012; Plante et al 2015 ). After initial replication in the liver of sensitive mice, the virus 
primarily targets muscle, joint, and skin fibroblasts, and viral RNA has been shown to persist in joint -associated tissue for months ( Couderc et al 2008;  Hawman et al 2013 ). These findings 
are relevant to human disease, as similar tissue and cell tropisms have been observed in 
CHIKV -infected patients ( Couderc et  al 2008), although detailed, comprehensive human 
biopsy evaluations have not been performed. Mice with severe disease also develop a central nervous system infection ( Couderc et  al 2008), as do some humans. One particularly sensitive 
animal model is the AG129 mouse, which has null mutations in the IFN -α/-β and - γ receptors 
(van der Broek et al 1995 ). Inoculation of AG129 mice with 1 × 10
4 plaque- form ing units of 
attenuated CHIKV vaccine strain 181/25 via the intradermal ( ID) route results in rapid onset 
of clinical signs of disease, including ruffled fur and hunched posture, followed by death within 3 to 4 days ( Partidos et al 2011). Although these mi ce are deficient in IFN signaling, they are 
able to mount B - and T -cell responses. Neutralizing antibodies are believed to be the primary 
effectors of protection against CHIKV , and indeed immune serum can afford protection in this model ( Partidos et al 2011). A number of CHIKV candidate vaccines have been evaluated in 
AG129 and related mouse models carrying a deficiency in only IFN -α/-β receptor signaling 
(A129) and have been shown to elicit neutralizing antibodies that protect from a lethal CHIKV challenge ( Partidos et al 2011; Plante et al 2011 ; Brandler  et al 2013; Metz et al 2013 ). Some 
of these candidate vaccines have also demonstrated efficacy in nonhuman primate challenge 
models ( Akahata et al 2010 ; Roy et al 2014 ) and have induced neutralizing antibody responses 
in humans ( Edelman et al 2000 ; Chang et al 2014 ; Ramsauer et al  2015 ). Based on these 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 27 findings, the AG129 mouse is considered an appropriate model for efficacy evaluation of 
CHIKV vaccines.  
The efficacy of the CHIKV C -E3-E2-6k-E1 mRNA vaccine and E2 and E1 mRNA vaccines 
(mRNA encodes envelope glycoproteins E2 or E1, respectively) given in various combinations 
of route of administration (ID or intramuscular [ IM]), number of vaccinations (1 or 2), and 
dose (2 µg or 10 µg) was determined in fem ale AG129 mice (lacking the IFN -α/β 
and -γ receptors). The C -E3-E2-6k-E1 mRNA vaccine provided full protection against the 
attenuated CHIKV strain 181/clone 25 (181/25) infection regardless of the route of administration, number of vaccinations, or dose. Two vaccinations of the E2 mRNA vaccine 
were also efficacious with either route of administration or dose, but a single vaccination was 
not effective with any combination of route of administration and dose. The E1 mRNA vaccine was only efficacious after 2 vaccinations of 10 μ g mRNA.  
Neutralizing antibody titers were measured in female 129S6 mice that received either 2  µg or 
10 µg of the CHIKV C -E3-E2-6k-E1 mRNA vaccine administered via the IM route either once 
or twice. Higher CHIKV neutralizing antibody titers were observed with higher vaccine dose levels and with greater number of vaccinations. The resulting CHIKV -specific antibodies 
neutralized all 3 CHIKV strains tested (37997, LaReunion, and Centers for Disease Control Caribbean), representing all major  CHIKV lineages. 
The efficacy of lower doses of V AL -181388 against a lethal challenge of CHIKV 181/25 was 
studied in female AG129 mice that were vaccinated via the IM route in various combinations 
of number of vaccinations (1 or 2) and dose (0.4 µg, 2  µg, or 10 µg). Following a lethal 
challenge with CHIKV 181/25 at either Day  56 or Day  112, IM vaccination with V AL -181388 
provided full protection for mice that received 2 μg or 10 μg VA L -181388, while mice that 
received 0.4 µg V AL -181388 had survival rates si milar to those in mice that received the 
negative control phosphate- buffered saline (ie, all mice were deceased by Day  5 after CHIKV 
challenge). Serum samples were tested for reactivity in an enzyme- linked immunosorbent 
assay for mouse IgG against CHIKV structural glycoproteins E1 and E2 and CHIKV lysate. 
For the Day  56 serum samples, antibody titers were both dose - and schedule- dependent, with 
higher titers in mice vaccinated twice compared to those vaccinated once. For Day  112 serum 
samples, antibody tite rs were increased in mice that received either 2  µg or 10 µ g VA L -181388. 
Chikungunya virus neutralizing antibody titers were also measured in Day  56 and Day  112 
serum samples. VAL -181388 induced high titers of CHIKV -specific neutralizing antibodies for 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 28 all 3 CHIKV strains tested in vitro (37997, LaReunion, and Centers for Disease Control 
Caribbean ) at Day  56 and for CHIKV strain 37997 at Day  112 (the only strain tested at 
Day 112), and the neutralizing antibody response was both dose - and schedule-dependent , with 
the highest titer observed in mice vaccinated with two 10 µg doses.  
The efficacy of VAL -181388 vaccine against a lethal challenge of CHIKV  181/25 was 
demonstrated in female AG129 mice. Mice were vaccinated via the IM route twice (prime and 
boost) w ith either 2  µg or 10  µ g o f  VA L -181388 or a phosphate- buffered saline  control. Mice 
that received V AL -181388 were fully protected. Results of enzyme -linked immunosorbent 
assay  analysis demonstrated that 2  vaccinations with either 2  μg or 10 μg 
VA L -181388- induced high antibody titers against CHIKV E1 and E2 glycoproteins and 
CHIKV lysate, with the highest titers against CHIKV lysate.  
Together, these studies have shown that the V AL -181388 vaccine is effective in producing an 
anti-CHIKV immune response in mice that is robust, both dose - and schedule -dependent, and 
protective against CHIKV challenge.  
In support of V AL -181388, the immunogenicity of similar mRNA -based influenza vaccines 
VA L -339851 (encoding hemagglutinin [HA] from the H7N9 influenza strain) and 
VAL-506440 (encoding HA from the H10N8 influenza strain) was assessed in cynomolgus 
monkeys to provide immunogenicity data in a larger animal species. Both vaccines utilize the same lipid nanoparticle ( LNP ) composition as V AL -181388 but contain different mR NA 
sequences. Vaccinations were given in various combinations of route of administration (ID or 
IM), number of vaccinations (1 or 2), and dose (0.2 mg or 0.4 mg). Anti -HA antibodies for 
VA L -339851 and V AL -506440 were detected starting on Day  15 for both routes  of 
administration . The peak level for anti -HA antibodies against V AL -339851 was reached by 
Days  29 to 36. The peak level for anti -HA antibodies against V AL -506440 was reached by 
Days  29 to 36 for animals dosed via the ID route and by Days  36 to 43 for  animals dosed via 
the IM route. Both the 0.2 mg and 0.4 mg doses achieved high levels of hemagglutination 
inhibition titers against H7 and H10  in cynomolgus monkeys, and ID administration was as 
effective as IM administration.  
1.2.2 Distribution  
Pharmacokinetic and drug metabolism studies are not normally performed for vaccines. 
However, because VAL -181388 is composed of an mRNA complexed with an LNP matrix, the 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 29 Sponsor has completed a distribution study with the similar mRNA -based influenza vaccine, 
VA L -506440 (encoding HA antigen from the H10N8 influenza strain), to assess the tissue 
distribution and persistence of the mRNA component. 
VA L -181388 consists of an mRNA Drug Substance (CX -000314) coding for the structural 
polyprotein (capsid and envelope glycoproteins E3, E2, 6k, and E1) of CHIKV combined with 
LNP components. Ultimately, the distribution of the mRNA is driven by the LNP components 
encapsulating the mRNA. Thus, using the same matrix, with the same route of administration, distribution is anticipated to be identical for any comparably sized mRNAs. Unlike DNA, mRNA has a finite lifetime within cells (measured in hours), does not  replicate or integrate, 
and is not anticipated to persist long -term following IM delivery. Hence, a single dose 
pharmacokinetic biodistribution study was performed in male mice with the similar 
mRNA- based influenza vaccine, V AL -506440, which uses the same  LNP composition as 
VA L -181388. 
Following a single IM dose in male mice, the peak plasma concentration of V AL -506440 was 
achieved at 2 hours after dosing and was followed by an apparent bi -exponential decline. The 
half-life of the mRNA was estimated at jus t under 10 hours, and the maximum concentration 
and area under the concentration versus time curve from the start of dose administration to the time after dosing at which the last quantifiable concentration was observed for V AL -506440 
were 5470 pg/mL and 35,500 pg•h/mL, respectively.  
VA L -506440 was broadly distributed into all analyzed tissues at 2 hours after dosing (bone 
marrow, brain, heart, kidney, liver, lung, lymph nodes [proximal and distal], gastrointestinal tract, stomach, spleen, testes , and the injection site), but with varying concentrations. When 
estimable, the half -life was variable among the tissues and ranged from 3.5 to 28.0 hours. 
With the exception of the muscle injection site, V AL -506440 mRNA levels were the highest in 
the proximal lymph nodes, followed by the distal lymph nodes, the spleen, and the liver, whereas the lowest exposures were observed in the jejunum, the brain, the stomach, and the heart. The relatively low level of exposure in the brain sugg ests limited penetration  of 
VA L -506440 across the blood-brain barrier.  
Overall, only a relatively small fraction of the administered V AL -506440 mRNA distributed 
to distant tissues, and it did not persist notably past 1 to 3 days in tissues other than the injection 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 30 site, the sple en, the liver, and the lymph nodes, tissues noted for their potential to take up and 
retain exogenous DNA. 
No absorption, metabolism, excretion, or drug-drug interaction studies have been performed. 
1.2.3 Toxicology  
1.2.3.1  Single -Dose Toxicity 
No single-dose toxicity s tudies were performed with V AL -181388. 
1.2.3.2  Repeat -Dose Toxicity  
The Sponsor has completed a repeat -dose IM toxicology study with V AL -181388 in rats, which 
is comp osed of mRNA complexed with an LNP matrix. Additional genetic toxicology studies 
have examined the mutagenic potential of the novel lipid excipients PEG2000- DMG and MC3, 
and an in vivo genetic bone marrow mutagenicity study has been performed with the similar 
mRNA- based influenza vaccine, V AL -506440, in support of V AL -181388. Results of these 
supportive studies are contained in the IB .  
The rat was chosen as the nonclinical species for the toxicity studies as it is an accepted species by the Organi sation for Economic Co- operation and Development, the European Medicines 
Agency, and the US Food and Drug A dministration  (FDA)  for the development of vaccines, 
and is a species with which the testing laboratories have ex tensive experience. The Sprague 
Dawley rat is considered a relevant species for safety evaluation with respect to desired and potential exagger ated immunological responses induced by vaccination with mRNA -based 
vaccines.  
Toxicological evaluation of the novel excipients in the LNP matrix (namely MC3 and PEG2000- DMG) requires the selection of species that reliably predict the occurrence of 
compleme nt activation. Complement activation is observed after intravenous ( IV) 
administration of a variety of compounds including liposomal drugs, contrast agents, pegylated proteins, and antibodies ( Szebeni 2014). The complement cascade is relatively conserved 
across species, and therefore the rat is likely to be sensitive to potential complement activation 
following administration of the LNP matrix. However, systemic complement activation is 
unlikely to be relevant for a product that is administered via the IM r oute where minimal 
systemic exposure is expected.  
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 31 In a repeat -dose study in rats, V AL -181388 was administered via IM injection  to groups of 
male and female Sprague Dawley rats at doses of 10, 40, or 160 μg/rat on Days 1, 22, and 43. 
Overall, V AL -181388 was clinically well tolerated up to 40 µg/dose, with more pronounced 
injection site reactions and s ystemic inflammatory responses observed at the 160 µg/dose. No 
mortality occurred during the course of the study. 
There were no V AL -181388- related changes in food consumption or ophthalmology. Lower 
body weight gain was observed during dosing weeks while the gain was higher during the 
off-dose weeks resulting in no effect on the overall body weight. V AL-181388- related clinical 
signs were observed at the injection site/area and were noted at all dose levels. Hematologic 
and clinical chemistry changes were consistent with administration of an immunostimulatory 
vaccine.  
Intramuscular dosing with V AL -181388 produced transient increases in infl ammatory 
cytokines IP -10, IL -1β, and MCP -1α, which were consistent with localized administration of 
an immunostimulatory vaccine.  With regard to the specific immune response t o the vaccine, 
significant dose -dependent anti -CHIKV antibody responses were noted at all dose levels. 
Responses were higher on Day  71 when compared with Day  44 results for animals dosed at 
greater than or equal to the 40 μg/dose. 
The majority of macroscopic  and microscopic findings observed were at or adjacent to the 
primary injection sites (subcutaneous inflammation, muscle fiber degeneration/necrosis) with 
other changes attributed (spleen, thymus, bone marrow, adrenal glands) to test item -induced 
stress or compensatory changes in both microscopic and clinical pathology. 
Most of the c hanges were either totally or partially resolved following a 4 -week recovery 
period. However, increases in prothrombin time for females at the 160 μg/dose correlating with 
partial recovery of microscopic findings seen at the injection sites, inguinal and popliteal 
lymph nodes, and/or sciatic nerve were observed. 
Based on these findings, the Sponsor has determined the no observed adverse effect level 
(NOAEL) to be 40 μg/dose for the IM route of administration in male and female rats.  
1.2.4 Genotoxicity  
The Sponsor has also evaluated the safety of the LNP composition of V AL -181388 in a series 
of genetic toxicology studies with the individual lipid components and in a study with the 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 32 similar mRNA -based influenza vaccine, V AL -506440, composed of an identical LNP 
composit ion as was used for VAL -181388. Neither the PEG2000- DMG nor the MC3 lipids 
produced any signs of genotoxicity or increased mutation frequency in either the Ames 
bacterial reverse mutation test or in a mammalian cell mutation study with human peripheral blood lymphocytes. 
In the mouse micronucleus in vivo mutation assay, V AL -506440 produced some toxicity and 
mortality in mice following IV dosing at doses ranging from 1.5 to 10 mg/kg. It must be noted 
that this test is designed to use a maximum tolerated dose (MTD) level via the systemic IV 
route, and these higher doses were also associated with significant bone marrow toxicity. Based 
on the known properties of the lipids, these findings are likely attributable to a complement 
activation -related pseudoallergy ( CARPA ) response ( Szebeni 2014) specific to IV systemic 
administration of LNPs such as those in both V AL -181388 and V AL -506440. The doses of 
VA L -506440 used in this in vivo genetic toxicology study represented the MTD levels , were 
several fold greater than the 10-μg doses typically administered IM or ID to mice , and are 
therefore anticipated to represent significantly greater systemic/plasma exposure than is 
expected via IM administration at the doses used in the Phase 1 clinical stud y with 
VA L -181388. 
At these doses, increased incidence of micronucleated immature erythrocytes indicative of 
chromosome damage was observed. However, since these doses were also associated with mortalities and severe clinical signs, they may have far exceeded the limit of to lerance in this 
assay. No substantial increases in the incidence of micronucleated immature erythrocytes , or 
substantial decreases in the proportion of immature erythrocytes, were observed at any of the other VA L -506440 doses in males, nor in the females t ested at the MTD of 1 mg/kg. Hence, 
despite notable toxicity at these extremely high doses evaluated, V AL -506440 was considered 
equivocal for the induction of chromosome damage in mouse immature erythrocytes. Given that the Sponsor ’s vaccines consist of mR NA complexed with LNPs, and LNPs have been 
shown to be associated with complement -mediated toxicity specifically following IV 
administration, these findings would appear to represent an artefactual response to high IV 
doses of LNPs. 
Further details on all nonclinical research on V AL -181388 can be found in the IB. 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 33 1.3 Clinical Studies  
No clinical studies have been conducted with V AL -181388. No reproductive or developmental 
toxicity studies have been completed to date with V AL -181388. Women of childbearing 
potent ial are included in th is Phase 1 clinical study. They must agree to be heterosexually 
inactive from at least 21 days prior to enrollment and through 3 months after the final 
vaccination or agree to consistently use protocol -specified approved methods of contraception 
from at least 21  days prior to enrollment and through 3 months after the final vaccination. 
VA L -181388 has not yet been administered to humans. Thus, information on possible risks 
and adverse reactions associated with IM administration of V AL-181388 is derived from:  
• Animal studies with V AL -181388, LNP components, or the similar mRNA -based influenza 
vaccine, V AL -506440  
• Published clinical data on other mRNA -based investigational medicinal product s and 
products encapsulated in LNPs of similar com positio n as the LNP formulation of 
VA L -181388  
• The Sponsor ’s recent experience with mRNA -based influenza vaccines, V AL -506440 and 
VA L -339851, using the same LNP matrix as V AL-181388 
Subjects receiving VAL -181388 are likely to experience mild- to-moderate injection site 
reactions as observed in studies in animals and generally observed and expected for other 
IM-administered vaccines. These local reactions may consist of pain, swelling, and erythema, 
which are transient and can be dose dependent. Possible mi ld to moderate systemic reactions, 
which are also transient, include fever, fatigue, chills, headache, myalgias, and arthralgias. In 
addition, other adverse events ( AEs) that have been generally associated with approved 
IM-administered vaccines have includ ed mild hematological and clinical chemistry 
abnormalities, which are usually reversible. 
Subjects receiving V AL -181388 could experience signs and symptoms compatible with a 
CARPA response, which has been observed in the administration of approved liposoma l 
products, contrast agents, pegylated proteins, and antibodies ( Szebeni 2014), as well as for 
small interfering RNA products formulated in LNPs ( Coelho et al 2013; Fitzgerald et al 2014 ). 
The signs and symptoms of CARPA resemble those of an acute hypersensitivity reaction. These 
signs can also be seen preclinically in toxicology species. However, complement activation is 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 34 far less likely to be associated with clinical signs for LNP products such as V AL -181388 that 
are administered IM at a much lower dose on a mg/kg basis than other clinical entities that 
cause CARPA in humans and nonclinical species.  
Moderna Therapeutics , Inc. currently has mRNA -based vaccines in 2 ongoing Phase 1 studies 
using different mRNAs but the same lipid composition as V AL -181388. The first is 
Study VA L -506440- P101 with V AL -506440 (encoding the HA antigen from the H10N8 
influenza strain) taking place in Germany; the sec ond is V AL -339851- P101 with V AL -339851 
(encoding the HA antigen from the H7N9 influenza strain), taking place in the United States. 
As of August 2016, over 200 subjects have received at least 1 dose of 25, 50, 75, 100, or 400 µg, 
and over 150 subjects have received 2 doses of 25, 50, or 100 µg. Vaccination has been given 
by both IM and ID routes. Both studies remain blinded for safety and are ongoing. However, grouped observational review of the data is possible, and summaries of safety have been reviewed by study -specific independent safety review committees prior to dose expansion and 
dose escalation. The reports of the se committees have been submitted to the respective 
regulatory authorities, the Paul Ehrlich Institute in Germany, and the FDA. No vaccine -related 
serious adverse events (SAEs) have been observed and all AEs have resolved without 
intervention. The most common AEs have been local reactions of pain, redness, and occasional 
induration, and mild to moderate non- specific systemic AEs such as headache and malaise. 
The majority of these events are mild or moderate in grade and the frequency and severity of 
these expected AEs appears to be dose related. In study V AL -339851- P101 (H7N9), one 
subject had asymptomatic severe (Grade 3) elevation of ALT and AST which resolved. Minimal to mild elevations in LFTs have been observed in additional subjects without a consis tent trend. Based on preliminary data, the safety experience to date can be summarized 
as follows: 
• There have been no unexpected clinically significant AEs or persistent AEs observed, with 
the exception of a single case of reversible and asymptomatic Grade  3 elevation of 
transaminases . 
• Local and systemic events are dose related and comparable in frequency and nature to 
adjuvanted non- live vaccines.  
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 35 • While these studies are still enrolling subjects as of November 2016, the safety profile of 
IM doses of V AL-506440 from 25 to 100 µg (prime and boost) and for VAL-339851 from 25 to 50 µg appears tolerable. 
1.4 Rationale for Study  
There are currently no effective therapies or approved vaccines to treat or prevent chikungunya, and effective mosquito control has proven challenging, even in higher income countries. 
Mosquito nets have limited ef fectiveness against the daytime -biting Aedes  mosquito. There fore, 
there is a need for a safe and effective prophylactic vaccine.   
Of the new approaches currently in development, virus- like particle vaccines and 
live-attenuated vaccines show the greatest potential from preclinical data ( Wang et al 2008; 
Akahata et al 2010; Darwin et al 2011 ; Brandler et al 2013). However, there are significant 
potential drawbacks with these 2 vaccine approaches. The virus -like particle -based vaccines 
are typically challenging to manufacture, particularly within the context of a disease of greatest 
relevance to developing countries where it is desirable to keep the technology simple and cost 
of goods low . The live -attenuated vaccines, on the other hand, carry the well -known safety 
concerns normally associated with this type of technology (potential of break-through infections and possible central nervous system sequelae, depending on the chosen virus 
back bone). Based on encour aging preclinical data with V AL -181388 and other similar 
mRNA- based vaccine candidates in the development pipeline, the Sponsor believes that 
VA L -181388 has the potential to be a tolerable and effective prophylactic vaccine against 
CHIKV . 
The purpose of t h e  VA L -181388-P101 study is to evaluate the safety and immunogenicity of 
VA L -181388 in healthy adult subjects  in a non- endemic chikungunya region . The primary 
objective is to characterize the safety profile of VAL -181388 versus place bo. The study will 
also evaluate immunogenicity by assessing serum neutralizing antibody titers and serum 
binding antibody titers to CHIKV proteins. 
1.5 Rationale for Dose Selection  
The clinical safety and efficacy of V AL -181388 have yet to be determined. The proposed dose 
levels of VAL -181388 to be evaluated in this study (25, 50, and 100 µg) are based on several 
data sources, including nonclinical studies (Section 1.2) using V AL -181388 and the similar 
mRNA- based influenza vaccine V AL -506440, and ongoing Phase 1 clinical studies with the 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 36 Sponsor’s other mRNA-based vaccines. The proposed clinical starting dose  of 25 μg provides 
a very large safety margin (285 -fold for a human subject weighing 70 kg) over the NOAEL in 
rats (102.6 μg/kg, based upon a mean body weight of 390 g) and yet still has the potential to 
elicit a meaningful immune response as demonstrated by nonclinical studies completed in mice 
and rats. The highest dose proposed for administration, 100 μ g, is expected to provide a safety 
margin of approximately 72-fold over the NOAEL in rats. 
1.6 Rationale for Study Design  
This study is designed  to evaluate the initial  safety and immunological outcomes of 
VA L -181388 for future clinical studies. Since the study will be conducted in non- endemic 
chikungunya region(s), where subjects are expected to be immunologically naive to the 
CHIKV components of VAL -181388, it is anticipated that a 2-dose schedule will be required 
to demonstrate a n adequate immune response. To ensure subject safety, dos e level cohorts will 
be sequential i n nature, starting with the lowest dose and requiring review by the SMC to 
advance to the next dose level cohort. For each cohort, a sentinel safety group of 4 subjects 
will be enrolled who will be random ly assigned  to VA L -181388 or placebo (3:1) and followed 
for 7 days after the first vaccination, with review of reactogenicity and safety laboratory results, 
prior to randomizing the remainder of the cohort. In addition, pause rules have been 
pre-established to trigger ad hoc SMC reviews, if required, and an internal safety team (IST) 
will review (blinded review) clinically significant safety laboratory test results, vital sign measurements, reactogenicity, and any AEs (all with toxicity scoring/grading) during the active 
vaccination phase of the trial.  Immun ogenicity will be assessed prior to each vaccination, and 
at 28  days and 6 and 12 months after the final vaccination . This allows assessment after the 
first and second vaccination, determination of best dose response , and duration of response 
through 1 year. 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 37 2 Study Objectives  
2.1 Primary Objective  
The primary objective of this study is to assess the safety of V AL-181388 relative to placebo. 
2.2 Secondary Objectives 
The secondary objective of the study is to determine the immunogenicity of 3 dose levels of 
VA L -181388 to inform the choice of dose for further development of this vaccine. 
Immunogenicity assessment will be based on changes from baseline in the following: 
• Serum neutralizing antibody titers to CHIKV  
• Serum binding antibody titers to CHIKV- specific proteins  
2.3 Exploratory Objective s 
The exploratory objectives of the study are to : 
• Assess the cross -reactivity of serum antibodies to related viruses, including alphaviruses 
and flaviviruses 
• Explore other assays to characterize the immune response to CHIKV  
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 38 3 Investigational Plan  
3.1 Study Design  
This is a Phase 1, first -in-human, randomized, observer -blinded, placebo- controlled, dose 
escalation study to evaluate the safety and immunogenicity of 3 dose levels of V AL -181388 in 
healthy adult subjects (18 to 49 years of age, inclusive). V AL -181388 is an mRNA -based 
vaccine being developed for prevention of disease associated with CHIK V infection . 
Chikungunya virus is a positive -sense, single -stranded RNA virus, of the alphavirus family, in 
the genus of the togavirus family. It can cause disease in humans and other mammals. It is an 
arbovirus that is transmitted by a mosquito vector ( Aedes spp ). Currently there is no approved 
vaccine to protect against this disease, which has recently spread through tropical regions. 
This is a 2 -part study, with Part A including dose escalation and safety and immune testing 
through 28 days following the final vaccination. Once subjects complete Part A they will 
transition  to Part B. Part  B is a continued safety follow -up through 12 months  and an 
assessment of immunogenicity and immune persistence at approximately 6 and 12 months after 
final vaccination.  
Part A  
In Part A, sequential dose escalation of V AL -181388 is planned in 3 dose level cohorts ( 25, 50, 
and 100 µg) with each subject receiving 2  vaccinations separated by 28 days. Subjects will be 
randomly assigned to receive either V AL -181388 or placebo.  
For each cohort, a sentinel safety group of 4 subjects will be enrolled who will be random ly 
assigned  t o  VA L -181388 or placebo (3:1) and followed for 7 days after the first vaccination 
with review of reactogenicity and safety laboratory results prior to randomizing the remainder 
of the cohort. An IST will oversee the safety of the trial and will review blinded safety data during Part A of the study to ensure adherence to the protocol, monitor safety laboratory test 
results and reactogenicity, and raise concerns to the SMC should there be safety issues or 
operational challenges that could affect subject safety. Only after review by the IST of the blinded safety data (reactogenicity, safety laboratory results , and AEs ) through 7 days 
following the first vaccination of the sentinel safety lead -in for each cohort planned, will 
approval be given to allow randomization of the remainder of that cohort. The SMC will approve escalation to the next higher dosing cohort after review of blinded safety data of the 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 39 currently dosed cohort through 7 days following the second vaccination and any cumulative 
safety data of all cohorts as the trial advances. The SMC will also be convened (ad  hoc 
meeting) if a pause rule is triggered.  
Dose Level Cohort Assignments:  VA L -181388 (or placebo) administered IM at Visit 1 and a 
second dose adminis tered 28 days later (Visit 4). 
Cohort 1 (N = 20): 25 µ g  VA L -181388 or placebo (ratio = 3:1) 
Cohort 2 (N = 20): 50 µ g  VA L -181388 or placebo (ratio = 3:1) 
Cohort 3 (N = 20): 100 µ g VA L -181388 or placebo (ratio = 3:1) 
Vaccine Administration and Dose Escalation Schema 
 
VA L -181388 (or placebo) will be administered as an IM injection (0.5 mL) into the deltoid 
muscle , preferably in the non-dominant arm, as a 2-dose schedule; the first dose will be given 
at Visit 1 followed by a second dose 28 days later.  VA L -181388 accountability, dose 
preparation, and administration will be performed by unblinded pharmacy personnel or 
unblinded designees who will not participate in any other aspect of the study. The remainder 
of the site staff and all subjects will remain blinded to treatment assignment.  
Consent and Screening will occur over a 28- day period prior to randomization. A total of 
20 subjects will be randomly assigned to each dose level cohort, 4 subjects (3 V AL -181388 
and 1 placebo) to the sentinel safety group and 16 subjects (12 VAL -181388 and 4 placebo) to 
the expansion group, resulting in 15 subjects being randomly assigned to V AL -181388 and 
5 subjects being randomly assigned to placebo (3:1 ratio overall).  Subjects meeting all 
eligibility criteria will re ceive the first  vaccination at Visit 1. Each subject will be monitored 
in the clinic for at least 1 hour following each vaccination for safety. Assessments will include 

Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 40 vital sign measurements and any immediate reactogenicity. Of note, on the day of vaccin ation, 
if a subject is noted to have a systolic or diastolic blood pressure, heart rate, or respiratory rate 
measurement that shows Grade 2 or higher toxicity after 2 measurements (even after relaxing 
or resting); has an acute  illness ; or has an oral temperature >38°C , the subject  should not 
receive a vaccination on that day and will need to return on subsequent day s for their 
vaccination.  
All subjects will return to the clinic at 7  (+3), 17 (±3), and 28 (+7) days following each 
vaccination. In addition, the sentinel safety group will return to the clinic at 1, 2, and 
21 (+3)  days following the first vaccination. A second vaccination will occur 28 days after the 
first vaccination (+7  days).  
Subjects will be instructed on recording solicited (local and systemic reactogenicity events) 
and unsolicited AEs, temperature, and medications (prescription or over -the-counter) on their 
memory aid (ie,  diary card). Subjects will also be asked to call/return to the clinic within 
24 hours if reactogenicity reaches Gr ade 3 or higher during the first 7 days following 
vaccination. As standard practice, a reminder call will be made to the subject by the site at least once during the first 7 days following each vaccination to answer any questions and ensure 
that the memory  aid is being completed correctly and consistently.  
Safety assessments will include toxicity grading of solicited (local and systemic reactogenicity 
events) and unsolicited AEs, vital sign measurements, physical examination findings, and clinical laboratory test results for hematology, serum chemistry, coagulation, and urinalysis. 
All unsolicited AEs will be collected and additional specific categories will include SAEs; AEs of special interest (AESIs); and medically attended AEs. Subjects will self -report  (using a 
memory aid) solicited (local and systemic reactogenicity events) and unsolicited A Es and 
medication usage (over -the- counter and prescription) through 28 days after each vaccination. 
In addition, subjects will be instructed to measure their oral temperature daily for the first 
7 days post vaccination and record that measure on the memory aid. At applicable clinic visits, the investigator will review the entries on the memory aid with the subject to ensure consistency. 
Safety laboratory tests will b e performed at Screening, on vaccination days (before dosing), 
and at 7 (+3) days after each vaccination. At 17 (±3) days following each vaccination and at 
28 (+7) days after the second vaccination, safety laboratory tests will be performed for coagulation and liver function tests only. The sentinel safety group will also have coagulation 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 41 and liver function tests collected at 21 (+3)  days after the first vaccination . Additional safety 
laboratory tests may be conducted at any time by the investigator if deem ed necessary.  
Blood samples for immunogenicity will be collected on dosing  days (pre -dose) and at 
28 (+7)  days after the final vaccination.  
Subjects unable to complete their second vaccination due to noncompliance with the visit 
schedule and not due to a cohort pause will still be required to follow the original visit and 
testing schedule. Specifically, these subjects will be asked to undergo blood collection to comply with a second immune test at 56 (+10) days (Visit 7) following the first vaccination.  
To allow cohort advancement, the following data from the highest dosed cohort are expected 
to be reviewed by the SMC: 1)  toxicity scoring of sa fety laboratory test results through 7 days 
following the second vaccination (through Visit  5); 2) toxicity scoring of vital signs and 
reactogenicity through 7 days following the first and second vaccination (through Visit  5); 
3) all unsolicited AEs (with grading and attribution). Data will be prepared by dose cohort  and 
timing relative to each vaccination. As safety data on all cohorts accumulate, the SMC also review ongoing AEs as well as cumulative safety laboratory test results, reactogenicity, and AEs across vaccine doses for subjects remaining in Part  A of the study, thereby providing a 
cumulative and comprehensive review of safety. Should a cohort pause occur due to pre-specified criteria, the SMC will be convened for an unscheduled (ad hoc) meeting and be 
provided with specific safety data related to the trigger of the pause.   
Part A is concluded for each subject when they return to the clinic for Visit 7 (28 days after 
final vaccination). At that time, subjects will transition to Part B of the study.  
The overview of study visit, safety, and immune assessments is presented in Table 3 -1 and the 
dosing schematic is presented in Figure 3 -1. 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 42 Table 3-1 Part A: Overview of Visit s 
Study visit  0 1 1aa 1ba 2 3 3aa 4 5 6 7 
Vaccination day   X      X    
Days relative to most recent 
vaccination  NA 0 1 2 7 17 21 28 7 17 28 
Window allowance  +28 0 0 0 +3 ±3 +3 +7 +3 ±3 +7 
Screening  X           
Physical examinationb X Xc   X  X Xc X  X 
Safety laboratory tests  X Xc   X X X Xc X X X 
Vital sign measurements  X Xd X X X  X Xd X  X 
Immune laboratory tests   Xc      Xc   X 
Study drug administratione  X      X    
Review of concomitant 
medications  X X X X X X X X X X X 
Review of safety (solicited and 
unsolicited)   Xd X X X X X Xd X X X 
a. Applies to sentinel safety group only.  
b. Sympto m-directed  after Screening . 
c. Obtained before study drug administration . 
d. Obtained before and after study drug administrat ion. 
e. Vaccination  cannot occur if systolic or diastolic blood pressure, heart rate, or respiratory rate measurement s 
show Grade 2 or higher  toxicity after 2 measurements ; if a subject has an acute illness ; or if a subject has an 
oral temperature >38°C . 
Figure 3-1 Dose Level  Schematic  
Abbreviation : SMC, Safety Monitoring Co mmittee.  
1. A sentinel safety group of 4 subjects in each cohort will receive VAL -181388 or placebo (3:1) on Day 1.  
2. Review of safety subject data by the internal safety team  (IST)  through at least 7 days after first vaccination (inclusive of 
reactogenicity, laboratory testing results, and adverse events) is required before the full cohort can be randomized.  
3. Safety assessment for dose escalation by the Safety Monitoring Committee  (SMC) will occur when all subjects in a dosing cohort 
have completed their 7-day post second vaccination visit (inclusive of reactogenicity, adverse events, and laboratory results) and 
will include safety data accumulation through the entire period for that  cohort and all previous dosing cohorts.  
4. The IST may perform additional reviews of blinded safety data during the active vaccination phase of the study, and will rais e 
concerns to the SMC if there are findings that could affect subject safety.  

Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 43 Part B  
To m onitor for longer- term safety and immune persistence, each subject will be entered into a 
continued blinded follow -up period (Part  B). This period will be conducted such that subjects 
and safety monitors will remain blinded to treatment assignment. Part B of the study is initiated 
for a subject once they have returned for Visit  7 (28 days after the second vaccination).  
Once entered into Part  B, each safety contact will occur by telemedicine (eg, telephone, text  
message, internet) every 28 (±7) days, and bl ood samples for immune persistence will be 
collected from each subject on Visit 1 2 (±15) and Visit 19 (+15) of the study. Each safety 
contact will capture outcomes of any AESI or SAE that remains unresolved since the last visit 
or is newly identified through scripted query. 
The telemedicine visits may require additional data through medically attended visits, in 
addition to medications and vaccinations taken by the subject during this time. Subjects will have consented during study enrollment to allow access to additional medical records needed 
to complete Part B, thereby allowing the blinding of the treatment assignment to be maintained.  
The overview of study visit, safety, and immune assessments is presented in Table  3-2. 
Table  3-2 Part B: Overview of Visits 
Study visit 8 9 10 11 12 13 14 15 16 17 18 19 
Study day from 1st dose, 
if 2nd dose not completed  84 112 140 168 196 224 252 280 308 336 364 392 
Study day from 2nd dose, 
if completed  56 84 112 140 168 196 224 252 280 308 336 364 
Window allowance  ±7 ±7 ±7 ±7 ±15 ±7 ±7 ±7 ±7 ±7 ±7 +15 
Safety contact  X X X X  X X X X X X  
Immune samples      X       X 
Serious adverse events  X X X X X X X X X X X X 
Adverse events of special 
interest  X X X X X X X X X X X X 
End of Study            X 
When all subjects have completed their final contact ( approximately 12 months  after their last 
vaccination ), immune testing is completed, and all queries resolved, the database will be locked 
and analyzed and a final clinical study report will be provided to regulators. 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 44 3.2 Selection of Study Population  
Healthy male or female subjects will be enrolled in the US (1  center). Approximately 
60 subjects  are planned to be randomized. 
3.2.1 Inclusion Criteria 
Each subject must meet all of the following criteria during the screening period to be enrolled 
in this study:  
1. The subject is male or female between 18 and 49 years of age, inclusive. 
2. The subject has a body mass index between 18 and 35 kg/m2, inclusive. 
3. The subject is considered by the investigator to be in good general health as determined 
by medical history, clinical laboratory assessments, vital sign measurements, and  physical 
examination findings at Screening.  
4. Female subjects must be non-pregnant and non- lactating and meet one of the following 
criteria: A) post-menopausal (defined as amenorrhea for 12 consecutive months without an alternative medical cause or document ed serum  follicle -stimulating hormone level in 
the post- menopausal range); B)  surgically sterile (ie, hysterectomy, bilateral tubal 
ligation, or bilateral oophorectomy). NOTE: procedures and laboratory test results  must 
be confirmed in the medical record, by physical examination, or by official written confirmation of a procedure; or C) if of childbearing potential, agrees to be 
heterosexually inactive from at least 21  days prior to enrollment and through 3 months 
after the final vaccination or agrees to co nsistently use any of the following methods of 
contraception from at least 21 days prior to enrollment and through 3 months after the final vaccination: condoms (male or female) with spermicide, diaphragm with spermicide, cervical cap with spermicide, intr auterine device, oral or patch 
contraceptives, Norplant
®, Depo-Provera®, or other FDA-approved contraceptive method 
which is designed to protect against pregnancy. Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods) and wit hdrawal are not acceptable 
methods of contraception. 
5. Male subjects must agree to consistently use appropriate contraception and to refrain 
from sperm donation through 3 months after the final vaccination. 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 45 6. The subject understands and agrees to comply with the study procedures and provides 
written informed consent before any study procedures are performed. 
7. The subject has access to a consistent and reliable means of telephone contact, which 
may be in the home, workplace, or by personal mobile electronic devic e. 
8. The subject agrees to stay in contact with the study site for the duration of the study, to 
provide updated contact information as necessary, and has no current plans to move from 
the study area for the duration of the study. 
3.2.2 Exclusion Criteria  
Subjects  meeting any of the following criteria will be excluded from the study:  
1. The subject has any ongoing significant chronic illness requiring medical or surgical care. Asymptomatic conditions or findings (eg, mild hypertension, dyslipidemia) that are not assoc iated with evidence of end -organ damage are not exclusionary provided that they 
are being appropriately managed and are clinically stable in the opinion of the investigator (ie, unlikely to result in symptomatic illness within the time -course of this 
study ).  
2. The subject is a female of childbearing potential and has a positive pregnancy test at 
Screening or on the day of vaccination. 
3. The subject has any abnormal screening laboratory result meeting the criteria listed 
below.  
a. Elevated l iver function tests ( aspartate aminotransferase, alanine 
aminotransferase, total or direct bilirubin , or alkaline phosphatase), 
elevated creatinine , or reduced platelet s with a toxicity score ≥ Grade 1  at 
Screening . Re- testing of these parameters is not allowed. 
b. Other than a) above, any safety laboratory test result (urine or serum) 
with:  
i. a toxicity score ≥ Grade 2   
ii. a toxicity score of ≥ Grade 1 deemed clinically significant  
4. The subject has participated in another investigational study involving any investigational product (ie, study drug, biologic, device) within 60 days, or 5 half-lives, whichever is 
longer, before planned date of first vaccination. 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 46 5. The subject has received any live attenuated or inactive vaccines within 4  weeks prior to 
enrollment, or plans to receive any vaccine during the active vaccination period (through 
4 weeks after their last planned vaccination).  
6. The subject has received (at any time) a vaccine for CHIKV , dengue, Yellow Fever, tick-borne encephalitis, or Japanese encephalitis.  
7. The subject has a history of confirmed or suspected CHIKV infection, has lived in a CHIKV -endemic area for >1 year , or has cumulatively spent more than 30 days in a 
CHIKV -endemic area within the last 5 years.  
8. The subject has reported previously participati ng in an investigational study involving 
LNPs . 
9. The subject has a history of hypersensitivity or serious reactions (eg, anaphylaxis, 
urticaria, other significant reaction) to previous vaccinations. 
10. The subject has any known or suspected autoimmune disease or immunosuppressive 
condition, acquired or congenital, as determined by medical history and/or physical 
examination.  
11. The subject has a history of arthritis (including inflammatory arthritis) or arthralgia . 
12. The subject has a neurologic disorder (eg, history of seizures, Guillain -Barre syndrome, 
dementia, vasculitis, or any known congenital or acquired disorder). 
13. The subject received immunoglobulins and/or any blood products within the 3 months preceding the administration of the study drug or plans to receiv e such products at any 
time during the study.  
14. The subject has had chronic administration (defined as more than 14 continuous days) of an immunosuppressant or other immune-modifying drug within 6 months prior to vaccine administration or plans to receive an y products during the active vaccination period 
(through 4 weeks after their last planned vaccination). An immunosuppressant dose of a glucocorticoid will be defined as a systemic dose of ≥10 mg of prednisone per day or equivalent. The use of topical, inha led, and nasal glucocorticoids will be permitted.  
15. The subject is currently receiving antipyretic or analgesic medication on a daily or every 
other day basis (a daily dose of ≤100 mg of aspirin given under the guidance of a 
physician is not a contraindication to enrollment). 
16. The subject has any acute illness at the time of enrollment (defined as the presence of a moderate or severe illness with or without fever, or an oral temperature >38.0°C on the 
planned day of vaccination). In such cases, subjects may be re-evaluated during the 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 47 screening period for resolution of the illness to allow at least 3 days of wellness prior to 
the planned vaccination. 
17. The subject has any significant disorder of coagulation (acquired or hereditary) requiring 
ongoing or intermittent treatment. Subjects receiving prophylactic antiplatelet medications, eg, low- dose acetylsalicylic acid (≤100 mg/day or equivalent), and without 
clinically apparent bleeding tendency, are eligible.  
18. The subject has a history of idiopathic urticaria. 
19. The su bject has a history of alcohol abuse or drug addiction within 1 year before the 
planned day of dose administration (self- reported).  
20. The subject has a positive test result for drugs of abuse at S creening.  
21. The subject has any abnormality or permanent body art (eg,  tattoo) that would obstruct 
the ability to observe local reactions at the injection site (deltoid region).  
22. The subject has any condition that, in the opinion of the investigator, would pose a health 
risk to the subject if enrolled or could interfere with evaluation of the study drug or 
interpretation of study results (including neurologic or psychiatric conditions deemed likely to impair the quality of safety reporting).  
23. The subject has a positive test result for hepatitis B surface antigen, hepati tis C virus 
antibody, or human immunodeficiency virus types 1 or 2 antibodies. 
24. The subject has a history of active cancer (malignancy) in the last 10 years. An exception is a subject with adequately treated nonmelanomatous skin carcinoma, who may 
participate in the study.  
25. The subject has donated blood or blood products >450 mL within 30 days of dosing. 
26. The subject has any screening vital sign measurement  (systolic or diastolic blood 
pressure, heart rate, or respiratory rate)  that shows greater than or equal  to Grade 2 
toxicity after 2  measurements . 
27. The subject is an employee or first-degree  relative of the Sponsor, PPD, or study site 
personnel. 
3.2.3 Subject Restrictions During the Study  
3.2.3.1  General and Dietary  
To avoid false positive drugs of abuse screening results, no food or drink containing poppy 
seeds (eg, specialty breads and muffins) will be allowed for 72 hours before the screening visit.   
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 48 3.2.3.2  Contraception and Pregnancy Avoidance Procedures  
Female subjects must be post -menopausal (defined as amenorrhea for 12 consecutive months 
without an alternative medical cause or documented serum  follicle -stimulating hormone level 
in the post -menopausal range) or surgically sterile (ie, hysterectomy, bilateral tubal ligation, or 
bilateral oophorectomy). NOTE: procedures and laboratory test results  must be confirmed in 
the medical record, by physical examination, or by official written confirmation of a procedure;  
or, if of childbearing potential, practicing a medically approved and highly effective method 
of contraception (defined as those which result in a low failure rate [ie, less than 1% per year] when used consistently and correctly). 
All female subjects of childbearing potential must have a negative pregnancy test at Screening 
and before dosing with study drug. Women of childbearing potential must agree to be 
heterosexually inactive from at least 21 days prior to enrollment and through 3 months after 
the fin al vaccination or agree to consistently use any of the following methods of contraception 
from at least 21 days prior to enrollment and through 3 months after the final vaccination: 
condoms (male or female) with spermicide, diaphragm with spermicide, cervi cal cap with 
spermicide, intrauterine device, oral or patch contraceptives, Norplant
®, Depo- Provera®, or 
other FDA -approved contraceptive method which is designed to protect against pregnancy . 
Periodic abstinence (eg, calendar, ovulation, symptothermal, post -ovulation methods) and 
withdrawal are not acceptable methods of contraception. 
Male subjects must agree to consistently use appropriate contraception and to refrain from 
sperm donation through 3 months after the final vaccination. Subjects will be provided with information on acceptable methods of contraception as part of 
the subject informed consent process and will be asked to sign a consent form stating that they understand the requirements for avoidance of pregnancy. 
3.3 Withdrawal of Subjects From the S tudy  
3.3.1 Reasons for Withdrawal  
Subjects can withdraw consent and discontinue from the study at any time, for any reason, 
without prejudice to further treatment. 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 49 The investigator can also withdraw a subject upon the request of Moderna Therapeutics, Inc. 
or if Moderna Therapeutics, Inc. terminates the study. Upon occurrence of a serious or 
intolerable AE, the investigator will confer with the Sponsor or designee. If a subject is 
discontinued because of an AE, the event will be followed until it is resolved or until stable.  In 
the event of a safety concern that results in withdrawal from further vaccination, the subject will be continued in the trial for safety evaluations.  
Every reasonable attempt will be made to follow withdrawn subjects for safety. The reason for 
subject withdrawal will be documented . 
The investigator, in consultation with the Sponsor’ s medical monitor, may withdraw a subject 
from further vaccination if the subject experiences any of the following: 1. Becomes pregnant;  
2. Develops, during the course of the study, symptoms or conditions listed in the exclusion 
criteria;  
3. Experiences an AE (other than reactogenicity) after vaccination that  is considered by the 
investigator to be related to treatment and is of Grade 3 (severe) or higher severity; 
4. Experien ces an AE or SAE that, in the judgment of the investigator, requires study drug 
withdrawal due to its nature, severity, or required treatment, regardless of the causal relationship to treatment; 
5. Experiences a clinically significant change in clinical labor atory test results , vital signs, or 
general condition that, in the judgment of the investigator, requires treatment withdrawal; 
6. Experiences anaphylaxis clearly attributed to study vaccine;  or 
7. Experiences generalized urticaria related to the study vaccine. 
The reason for withdrawing from further vaccination will be recorded. In addition, if a subject refused further vaccination they will be continued in the trial with all planned visits  and 
assessments. The recording of the reason for vaccination refusal will be documented. 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 50 3.3.2 Handling of Withdrawals  
When a subject withdraws from the study, the reason(s) for withdrawal will be recorded by the 
investigator on the relevant page of the electronic case report form ( eCRF ). These subjects will 
also be requested to com plete all Visit 7 assessments. Any subject who fails to return for final 
assessments will be contacted by the site with a minimum of 3 telephone call attempts, 
followed by a certified letter.  
Lost to follow -up is defined by the inability to reach the subj ect after a minimum of 
3 documented telephone calls, faxes, text  message s, or emails as well as lack of response by 
subject to 1 registered mail letter. All attempts should be documented in the subject’ s medical 
records.  
3.3.3 Replacements  
If a subject is withd rawn, who is significantly outside the allowed vaccination window, or is 
lost to follow -up from the study, the decision on whether or not to replace the subject will be 
made by the Sponsor in conjunction with the princip al investigator.  
3.4 Study Treatments  
3.4.1 Method of Assigning Subjects to Treatment Groups  
Subjects will be randomly assigned in a sequential manner to a dose level cohort after all entry 
criteria have been satisfied on Visit 1. A randomization table will be pre -generated, and only 
the unblinded pharmacy personnel will have controlled access. Within each dos e level  cohort, 
20 subjects will be randomly assigned to receive either V AL -181388 ( 25, 50, or 100 µg) or 
placebo in an overall ratio of  3:1. The first 4 subjects within each  dose level  cohort will be 
randomly assigned to receive VAL -181388 ( 25, 50, or 100 µg ) or placebo in a 3:1 ratio. Only 
after review by the IST of the blinded safety data (reactogenicity, safety laboratory results , and 
AEs) through 7 days following the first vaccination of the sentinel safety lead -in for each 
cohort planned, will approval be given to allow randomization of the remainder of that cohort. 
The remaining 1 6 subjects within each dose level cohort will be randomly assigned to receive 
either V AL -181388 (25, 50, or 100 µg ) or placebo in a 3:1 ratio.  
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 51 3.4.2 Treatments Administered  
Up to 60 subjects will receive 1 of the following treatments based on the treatment to which 
they are randomly assigned. Dos e level  cohorts will advance in a sequential manner after 
review of all safety data through 7 days after the final vaccination of the previous dose level 
cohort by the SMC (inclusive of reactogenicity, safety laboratory test results , and AEs). All 
vaccines will be administered as a 2 -injection schedule  (28 days apart), into the deltoid muscle 
(IM) , preferably in the non-dominant arm: 
• Cohort 1 ( N = 20): 25 µ g  VA L -181388 or placebo (ratio = 3:1) 
• Cohort 2 ( N = 20): 50 µ g  VA L -181388 or placebo (ratio = 3:1) 
• Cohort 3 ( N = 20): 100 µ g VA L -181388 or placebo (ratio = 3:1) 
The clinic will be appropriately staffed, trained on emergency resuscitation, and have stocked 
available rescue medications (such as epinephrine, steroids, antihistamines, and IV fluids) 
should any severe reaction (eg, anaphylactoid or profound urticaria) occur which requires immediate intervention.  
3.4.2.1  Dose Escalation  
Internal Safety Team  
An IST will oversee the safety of the trial and will review blinded safety data during Part  A of 
the study to ensure adherence to the protocol, monitor safety laboratory test results and 
reactogenicity, and raise concerns to the SMC should there be safety issues or operational 
challenges that could affect subject safety. Pause rules have been pre -established to trigger 
ad-hoc SMC reviews, if required (Section  3.4.2.2 ), and the IST will review (blinded review) 
safety laboratory test results, vital sign measurements, reactogenicity, and any AEs (all with 
toxicity grading) during the ac tive vaccination phase of the trial. In addition, recruitment rates, 
timing of vaccination sequence, and window adherence will be reported to the IST. The 
chairperson of the IST may request that additional data be provided to the SMC that relates to the safety of subjects (eg, study conduct, quality issues, or safety concerns).  
The 4 subjects in the sentinel safety group will receive VAL -181388 or placebo at Visit 1. The 
IST will review blinded safety data through at least 7 days after vaccination, inclusive of 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 52 reactogenicity, laboratory results, and any AEs from all subjects in the sentinel safety group. 
The IST is responsible for opening randomization to the remainder of the dose level cohort for 
that dose level after review of the safety data.  
At minimum, the IST will be composed of the Sponsor ’s study medical monitor lead, the 
contract research organization ’s medical monitor, and the principal investigator. The 
pharmacovigilance officer will oversee safety aspects of the study and will participate as needed. Additional ad hoc members may be included as needed. 
Safety Monitoring Committee 
Dose escalation will proceed  following review of blinded safety data by the SMC of the entire 
dose level  cohort through 7 days following the second vaccination. In addition, the SMC will 
review prior dos e level  cohort reactogenicity and accumulated AEs at the time of the scheduled 
safety review to allow the SMC an aggregate view of overall safety. The SMC safety data assessment will include the following  blinded summary data: 1) toxicity scoring of safety 
laboratory test results through 7 days following the second vaccination (through Visit  5); 
2) toxicity scoring of vital signs and reactogenicity through 7 days following the first and second vaccination (through Visit  5); 3)  all unsolicited AEs (with grading and attribution). 
Data will be prepared by dose cohort  and timing relative to each vaccination. As safety data on 
all cohorts accumulate, the SMC also review ongoing AEs as well as cumulative safety laboratory test results, reactogenicity, and AEs across vaccine doses for subjects remaining in 
Part A of the study, thereby providing a cumulative and comprehensive review of safety. 
Should a cohort pause occur due to pre -specified criteria, the SMC will b e convened for an 
unscheduled (ad hoc) meeting and be provided with specific safety data related to the trigger of the pause. If no pause rules  (Section 3.4.2.2) are triggered  or any other safety concerns are 
identified , the SMC may recommend escalation to the next dose level.   
In addition, the Sponsor will submit available safety data for the 25 and 50 µg dose cohorts and recommendations of the SMC  to the Center for Biologics Evaluation and Research 
(CBER) prior to initiation of the 100 µg cohort. 
The SMC may recommend advancement to the next dos e level , request additional information 
prior to providing a recommendation, recommend stopping the study, recommend changes to 
study conduct and/or the protocol, or recommend additional operational considerations due to safety issues that arise during study conduct . The Sponsor has the authority to accept (or 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 53 amend) the SMC recommendations, to stop the study  at any time, to request a cohort pause for 
safety concerns (to be addressed by the SMC), and to request additional consultation during 
study conduct for either safety concerns or operational issues. The SMC will also be convened 
should a pause rule (Secti on 3.4.2.2) be triggered or at the request of the IST, the investigator, 
or the Sponsor. 
The SMC will be comprised of 3 voting and independent members who are medical doctors 
familiar with Phase 1 clinical trial and safety review and independent from the trial. In addition, a biostatistician not associated with the trial will prepare the safety data (non -voting member), 
and a coordinator not associated with the trial will organize and record decisions of  the SMC 
(non- voting member). The SMC may decide to include a non- medical person to weigh in on 
ethical issues if the need arises.  
3.4.2.2  Pause Rules  
During the active vaccination period, if any of the following events occur and are assessed to 
be potentially VA L -181388 related, the study will be paused for further enrollment and 
vaccination and an unscheduled SMC will be convened to assess specific data concerns and make recommendations: 
• Two or more severe reactogenicity events of the same nature (whether syst emic or local) 
within a dose cohort following any single (eg, the first, the second) vaccination 
• Two or more Grade 3 (or greater) laboratory toxicit ies within a cohort  and of the same 
nature 
• One or more SAEs assessed as vaccine related, including any systemic hypersensitivity 
reaction  
An unscheduled SMC may also be convened (with vaccination pausing if deemed necessary), 
by the investigator, IST, or Sponsor, if any other significant safety or tolerability issues are 
identified in the comprehensive review of  available data that warrant further evaluation before 
additional subjects are dosed. This may include emerging nonclinical data, clinically relevant 
AEs, or relevant data from other sources indicating safety concerns even if the event(s) per se 
does not m eet the criteria specified in this section.  
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 54 Should a pause be triggered in the study, then each subject’ s visits will continue until the next 
scheduled vaccination visit. Should a pause affect a subject ’s vaccination visit, then the 
window for that subject ’s vaccination visit will be suspended until the pause is lifted and 
vaccination can resume. Once the pause is lifted at the site, vaccination should be reinstated as 
soon as possible. Visits should thereafter be scheduled as if they had received their sec ond 
vaccination within the 28 (+7) day time window. 
Should a pause be prolonged such that the vaccination sequence cannot establish a 28 (+  7) day 
time window, the Sponsor has the option to add additional subjects in a dosing cohort to 
achieve the original  number of subjects planned to be dosed within the 28 (+7) day time 
window. If a subject is in the screening period during this pause and more than 28 days has transpired, they may be rescreened for study eligibility as long as they continue to provide consent to participate in the study.  
The objectives of the study are to characterize safety, tolerability, and immunogenicity of 
multiple ascending doses of VAL -181388. Thus, this protocol is written with some flexibility 
to reflect the dose- finding nature of  this Phase 1 clinical study. Modifications to the dose level 
may be required to achieve the scientific goals of the study and/or to ensure appropriate safety monitoring of the study subjects. Identity of Investigational Product 
VA L -181388 is composed of 1.6 mg/mL of CX -000314, the V AL -181388 mRNA drug 
substance, formulated in a mixture of 4 lipids, including MC3 (DLin- MC3 -DMA, a novel 
ionizable lipid), cholesterol, DSPC (1,2- Distearoyl -sn-glycero -3-phosphocholine), and 
PEG2000- DMG (1,2 -Dimyristoyl -sn-glyce rol, methoxypolyethyleneglycol), to form an 
mRNA- lipid complex ( LNP) in 7.0% propylene glycol, 1 mM DTPA  
(diethylenetriaminepentaacetic acid) , 100 mM Tris buffer.  
The placebo is 0.9% Sodium Chloride Injection, USP or BP. 
3.4.3 Management of Clinical Supplies  
3.4.3.1  Study Drug Packaging and Storage  
Moderna Therapeutics, Inc. will provide the investigator and study site with adequate 
quantities of V AL -181388. The placebo (0.9% Sodium Chloride Injection, USP or BP) is 
commercially available and will be supplied by the study site. VA L -181388 will be labeled 
“for clinical trial use ” and have all required labeling per regulations. V AL-181388 will be 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 55 supplied to the pharmacy in an unblinded manner. Each vial will be individually labeled for 
future subject identification purpos es.  
VA L -181388 I njection will be supplied in 2 -mL glass vials with a 0.5 -mL fill volume  at a 
concentration of 1.6 mg/mL . The unblinded study site pharmacy personnel will prepare a single 
dose for each subject based on the dose level  cohort and randomization assignment. A single 
vial may be used for multiple subjects in a given day as long as the storage conditions are met 
and the vaccine is not refrozen. A pharmacy manual will be available and training provided to 
ensure pharmacy staff can comply with all vaccine storage, preparation, administration, and 
drug accountability procedures.  
VA L -181388 must be stored in a secure area with limited access (unblinded pharmacy staff 
only), protected from moisture and light, and be stored at −20°C ± 5°C. The freezer should 
have an automated temperature recording and alert system. There must be an available back -up 
freezer. The freezers must be connected to a  back -up generator. The pharmacy must have in 
place a 24 -hour alert system that allows for rapid  response in case of freezer malfunctioning. 
In addition, drug accountability study personnel (eg, the unblinded pharmacy staff) are required 
to keep a temperature log to establish a record of compliance with these storage conditions. 
The placebo will be s tored according to the instructions on the product label and must also 
comply with storage in a restricted access area. Only drug accountability personnel should 
have access to the products used in this study.  
The site is responsible for report ing any VA L -181388 that was not temperature controlled 
during shipment or during storage to the unblinded site (pharmacy) monitor  and to the Moderna 
Therapeutics, Inc. Clinical Supply Manager. Such VA L -181388 will be retained for inspection 
by the unblinded monitor and next steps discussed with the Moderna Clinical Supply Manager. 
VA L -181388 determined to be questionable or unsuitable may be quarantined or disposed of 
upon approval by Moderna according to approved methods. 
3.4.3.2  Study Drug  Accountability 
It is the investiga tor’s responsibility to ensure that that the unblinded pharmacy personnel 
maintain accurate records of receipt of all VA L -181388, including dates of receipt. In addition, 
accurate records will be kept regarding when and how much VA L -181388 is dispensed and 
used by each subject in the study  (including documentation of each dilutional record used to 
prepare the vaccine for injection) . Reasons for departure from the expected dispensing regimen 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 56 must also be recorded. To satisfy regulatory requirements regarding drug accountability, all 
VA L -181388 will be reconciled and retained until study conclusion. At that time, VA L -181388 
will be destroyed or returned to the Sponsor according to applicable regulations. 
3.4.4 Blinding  
This is an observer -blinded  study. The investigator, study subjects, site monitors, and study site 
personnel will be blinded to the study drug administered, with the following exceptions: 
• Unblinded pharmacy personnel (of limited number) will be assigned to perform drug 
accountability p rocedures and to prepare and administer VA L -181388 (or placebo)  to all 
subjects. The unblinded pharmacy personnel will have no other study functions other than 
study drug management, documentation, accountability, preparation, and administration. 
They will not be involved in subject evaluations and will not reveal the study drug identity 
to either the subject or study site personnel involved in the conduct of the study, except  in 
the case of an emergency.  
• An unblinded study monitor, not involved in other aspects of monitoring, will be assigned as the drug accountability monitor. They will have responsibilities to ensure the site is 
following all proper drug accountability, preparation, and administration procedures.  
• An unblinded statistician will provide a descriptive analysis of safety and immunological 
endpoints after the completion of each dosing cohort. The interim analyses of 
immunogenicity data will be performed as outlined in Section 3.6.7. 
The treatment assignment will be concealed by having  the unblinded pharmacy personnel 
prepare the study drug in a secure location that is not accessible to other study personnel. The 
syringe used will maintain the blind at the time of vaccination (eg, a sleeve will be used should 
the vaccine substance be distinguishable in appearance between the V AL -181388 and placebo). 
The unblinded pharmacy personnel  will conduct the vaccination procedure. Once the 
vaccination is completed, the blinded study staff will take over further assessments and 
interactions with the subjects. Access to the randomization code will be strictly controlled at 
the pharmacy.  
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 57 3.4.5 Breaking the Blind  
A subject or subjects may be unblinded in the event of an SAE or other event, or if there is a 
medical emergency requiring the identity of the drug to be known to properly treat a subject. 
If a subject becomes seriously ill or pregnant during the study, the blind will be broken only if knowledge of the administered study drug will affect that subject ’s treatment options. In the 
event of a medical emergency requiring identification of the study drug administered to an individual subject, the investigator will make every attempt to contact the medical monitor to explain the need for opening the code within 24 hours of opening the code. The investigator will be responsible for documenting the time, date, reason for the code break, and the names 
of the personnel involved. 
In addition to the aforementioned situations where the blind may be broken, the data will also 
be unblinded to a statistical team at specif ied time points for each data lock  as outlined in 
Section 3.6.7. At the interim analysis of safety, reactogenicity , and immunogenicity data 
collected from Day 1 to Month 7, access to individual listings (unblinded) will be available to 
a restricted number of identified Sponsor team members and the clinical research organization  
unblinded statistician. Study sites will remain blinded.  
3.4.6 Treatment Compliance  
All doses of study drug will be administered at the study site under direct observation of study site personnel and appropriately recorded (date and time) in the eCRF . Site personnel will 
confirm that the subject has received the entire dose of study drug. If a subject does not receive 
study drug or does not receive all of the planned doses, the reason for the missed dose will be 
recorded  in the source documents.  
Subjects that miss the second vaccination due to noncompliance with the visit schedule and not due t o a cohort pause will still be required to follow the original visit and testing schedule. 
Specifically, these subjects will be asked to undergo blood collection to comply with a second immune test at 56 (+10) days (Visit 7) following the first vaccination . 
The study site is responsible for ensuring subjects comply with the study windows allowed. 
Should a subject miss a visit, every effort will be made to contact the subject and achieve a 
visit within the defined visit window . If a subject exceeds their pos t-vaccination visit in excess 
of 28 days from the scheduled visit or misses a vaccination schedule by more than 28 days (eg, 28 days beyond the scheduled time of vaccination) then that visit will be classified as a missed 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 58 visit and the subject will continu e with subsequent visits for P arts A and B of the study . All 
safety requirements of the missed visit will be captured and included in the follow -up visit (eg, 
safety laboratory testing, memory aid  review for reactogenicity, as applicable).  
3.4.7 Prior and  Concom itant  Medications 
3.4.7.1  Prior Medications and Therapies  
Information about prior medications (including any prescription or over -the-counter 
medications, vaccines, or blood products) taken by the subject within the 30 days before 
providing informed consent (or as  designated in the inclusion/exclusion requirements) will be 
recorded in the subject ’s eCRF.  
3.4.7.2  Concomitant Medications and Therapies  
In Part  A of the study, concomitant medications include all medications (including vaccination 
outside of trial) taken by the  subject from the time of signing the informed consent form (ICF) 
through 28 days after the second vaccination (Visit  7) and will be recorded in the eCRF. In 
Part B, receipt of immunomodulators (including vaccines), immunosuppressants, or other 
concomitant medications that could potentially impact immune response will be collected 
through the end-of-study ( EOS ) visit.   
Subjects are prohibited from receiving immunoglobulins and/or any blood products within the 3 months preceding the administration of the study drug or at any time during the study.  
Acetaminophen may be allowed at the discretion of the investigator. A daily dose of ≤100 mg 
of aspirin given under the guidance of a physician is not a contraindication to enrollment.  
To allow accurate assessment of analgesic/antipyretic use during the 7 days after each 
vaccination , subjects will be inquired directly as to use (absent or present) and if used will be 
inquired for treatment or prophylaxis. 
Chronic administration (defined as more than 14 continuous days) of an immunosuppressant 
or other immune modifying drug within 6 months prior to vaccine administration or any such products during the active vaccination period (through 4 weeks after their last planned vaccination) is prohibited. An immunosuppressant dose of a glucocorticoid will be defined as 
a systemic dose of ≥10 mg of prednisone per day or equivalent. The use of topical, inhaled, 
and nasal glucocorticoids will be permitted.  
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 59 Receipt of any other licensed vaccines (inactivated or live vaccines) wit hin 4 weeks prior to 
dose administration or planned within 4 weeks from any dose administration is an exclusion 
criteria . 
Concomitant medications (including vaccinations) will be coded using the WHO Drug 
Dictionary. If prohibited drug therapy is taken, a j oint decision will be made by the investigator 
and the Sponsor to continue or withhold further vaccination of the subject based on the time the medication was administered and its pharmacology and pharmacokinetics, and whether the use of the medication wil l compromise the subject safety or interpretation of the data. It is the 
investigator ’s responsibility to ensure that details regarding the concomitant medication are 
adequately recorded in the eCRF.  
3.5 Study Procedures  
Before performing any study procedures,  all potential subjects will sign an ICF. The 
investigator must address all questions raised by the subject before the subject signs the consent form. The investigator will also sign the ICF. Subjects will undergo study procedures at the time points specif ied in the schedule of events ( Table  6-1 and  Table  6-2).  
At any time during the study a subject can be seen for an unscheduled visit. This may be 
prompted by abnormal laboratory test results, reactogenicity issues, or new or ongoing AEs. The site  also has the discretion to make reminder telephone calls or text  messages  to inform 
the subject on visits, request further laboratory assessments, review memory aid  content 
requirements, and follow -up on ongoing or outstanding issues.  As standard practice, a reminder 
call should be made to the subject by the site at least once during the first 7 days following each vaccination to ensure that the memory aid is being completed correctly  and consistently . 
Specific activities at each visit are outlined in Table  6-1 and Table  6-2 and may include the 
following: 
• Confirm subject identification and contact information  
• Record vital  sign s (toxicity graded) and perform physical exam ination  
• Review memory aid  
• Grade reactogenicity  
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 60 • Assess for new AEs and follow up on any outstanding AEs (including grading and 
attribution )  
• Review any new laboratory test results (toxicity graded) and identify any laboratory tests 
that should be repeated 
• Record any concomitant medi cations and vaccinations since last visit 
• Collect blood samples as indicated by visit 
• Vaccinate (Visits 1 and 4 only) 
• Schedule follow up appointments 
• Complete all eCRFs  
• Enroll subject in the continued blinded follow up period (Part B) (after subject has 
returned for Visit 7 [28 days following the second vaccination] in Part A) 
3.5.1 Safety Contact  
Once entered into Part  B, each safety contact will occur by telemedicine (eg, telephone, text 
message, internet), and blood samples for immune persistence will be colle cted from each 
subject at the time points indicated in Table  6-2. 
Safety contacts  must be performed  by appropriately trained study site staff. If the initial contact  
is unsuccessful, the study site staff should make a total of 3 attempts for each scheduled safety 
contact . All attempts to contact the subjects will be recorded in the source documents.  The 
safety contact  is considered missed if there is a failure to contact the subject by the time of the 
succeeding visit (every 28 days  plus window allowance ).  
These contacts will follow a script, which will facilitate the collection of relevant safety 
infor mation. Each safety contact will capture outcomes of any AESI or SAE that remains 
unresolved since the last visit or is newly identified through scripted query. Additional data may be requested through medically attended visits, and medications and vaccina tion will be 
recorded as part of the medical intake for each telemedicine visit. All safety information 
described by the subject must be documented in the source documents and not documented on 
the script used for the safety contact.  
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 61 3.5.2 Completion of Memory A id 
The memory aid utilized will be a diary card  (paper or electronic device ) and is a method to 
record systematic collection of AE information from the subject; this information is subject to 
potential change based on further questioning and/or follow -up by study staff. Each subject 
will be instructed to complete a memory aid  to describe: 
• Solicited local and systemic AEs ( Section 3.5.6) occurring (with appropriate 
documentation to allow severity grading by the investigator)  during the day of each dose 
administration and for the following 7 days  
o Daily oral body temperature measurement is to be performed at approximately the same 
time each day using the thermometer provided by the study site. If body temperature is 
taken more than once in a given day, only the highest temperature reading will be  
recorded . 
o For solicited local AEs that require measurement, the measurement of size will be 
performed using the ruler provided by the study site. 
• All medications (excluding vitamins and minerals) taken during the day of each vaccine 
administration and for the following 28 days  
• Any uns olicited AE during the first 28 days following each vaccination  
Study staff will review the information regarding solicited and unsolicited AEs, temperatures, and concomitant medications  during the clinic visit.  This information will be recorded in the 
subject ’s source documents and the eCRF. 
3.5.3 Immunogenicity  Assessments  
Blood samples for immunogenicity assessment will be collected at the time points indicated (Table  6-1 and Table  6-2). Sample aliquots will be designed so as to ensure that back-up 
samples  are available and adequate vial volumes will allow for testing needs. The actual time 
and date of each sample collected will be recorded in the eCRF and unique sample 
identification will be utilized to maintain the blind at the laboratory at all times and  to allow 
for automated sample tracking and housing. Handling and preparation of the samples for 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 62 analysis, as well as shipping and storage requirements will be provided in a separate laboratory 
manual.  
Immunogenicity endpoints are provided in Section 3.6.2. 
3.5.4 Total Blood Volume  
The approximate blood volumes to be collected from each subject during the study are provided in Table  3-3. 
Table  3-3 Total Blood Volume  
Assessment  Blood Volume 
per Sample  Scheduled Number of 
Collect ionsa Total Amount of 
Scheduled Blood 
Clinical Laboratory Assessments  
Hematology 2 mL 5 10 mL 
Serum chemistry  6 mL 8 (9 if sentinel)  48 mL (54 mL if 
sentinel)  
Coagulation  4.5 mL  8 (9 if sentinel)  36 mL (40.5 mL if 
sentinel)  
Serologyb 6 mL 1 6 mL 
Immunogenicity Assessments  
Serum neutralizing assay  7 mL 5 35 mL 
Serum binding assay  4 mL 5 20 mL 
Exploratory antibody assay s 10 m L 5 50 mL  
Subject Total  205 mL (215.5 mL if 
sentinel)  
a Additional blood collections may be required at the discretion of the investigator to follow up on abnormal 
results. Subjects in the sentinel safety group  will have 1 additional collection for serum chemistry and 
coagulation samples; thus , the total volume  for these subjects will be 2 15.5 mL. 
b Serology testing will include hepatitis B surface antigen, hepatitis C virus antibody, and HIV virus type  1 
and 2 antibodies. A separate counseling and consenting for HIV testing will occur.  
3.5.5 Safety Assessments 
Safety  assessments will include monitoring and recording of the following: 
• Solicited (local and systemic reactogenicity events) and unsolicited AEs  
• SAEs  
• AESIs  
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 63 • Clinical laboratory test results  including hematology, serum chemistry, coagulation, and 
urinalysis  
• Vital sign measurements  
• Physical examination findings  
3.5.6 Solicited Safety Measurements  
The term “reactogenicity” refers to selected signs and symptoms (AEs) occurring after dose 
administration, to be collected by the subject during the day of each dose administration and 
for the following 7 days using self -reporting and the memory aid . Subjects will be instructed 
to call or return to the clinic within 24 hours if reactogenicity reaches Grade 3 or higher during 
the first 7 days following vaccination.  
The following AEs are included in the memory aid . 
Solicited local AEs include: 
• injection site induration /swelling  
• injection site ten derness  
• injection site erythema /redness 
• injection site pain  
Solicited systemic AEs include: 
• body temperature (oral) 
• generalized myalgia (muscle ache or pain)  
• generalized arthralgia (joint ache or pain)  
• headache  
• fatigue/malaise  (unusual tiredness) 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 64 • nausea/ vomiting  
• diarrhea  
The AEs  will be recorded  by subjects daily using the memory aid; where appropriate 
reactogenicity measurements will be taken using the tools provided (oral thermometer and 
measuring device). The investigator will later review, confirm, grade, and attribute AEs including reactogeni city, as absent  (Grade 0) , mild (Grade 1), moderate (Grade 2), severe 
(Grade 3), or potentially life threatening (Grade 4) . The Toxicity Grading Scale for Healthy 
Adult and Adolescent V olunteers Enrolled in Preventative Vaccine Clinical Trials (CBER  2007; Table  6-3) will be used to grade reactogenicity reactions . If a solicited local or 
systemic AE continues beyond 7 days after dose administration, it will also be recorded as an 
AE in the eCRF from 8 days after vaccination until resolved or stable. 
Other solicited reactions: 
Use of analgesics  and/or antipyretics will be recorded as absent or present, and it will be 
indicated if they were used for treatment or for prophylaxis.  
Solicited local and systemic AEs (including body temperature) will be collected using the 
memory aid  during the day of each dose administration (at approximately 6 hours) and for the 
following 7 days . To improve recall for the  next visit, subjects will record incidence of 
unsolicited AEs and medication using the memory aid  until approximately 28 days after each 
vaccine administration.  
All AEs necessitating an un scheduled physician visit, medical attention, or leading to 
withdra wal from the study will also be collected throughout Part A of the study, and all AEs 
will be monitored until resolution or, if the AE becomes chronic, a cause is identified. If an AE is unresolved at the conclusion of Part A of the study, a clinical asses sment will be made by 
the investigator and the medical monitor to determine whether or not continued follow -up of 
the AE is warranted. The relationship of the study drug to any AE and any SAE will be 
determined by the investigator as related  or not related . All AEs resulting in withdrawal of the 
subjects from the study will be documented in the source documents and in the eCRF. 
For Part B of the study, a script will be utilize d to query for any new SAE s or AESI s and proper 
documentation will be obtained to allow an assessment of relatedness to vaccination or study 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 65 participation. All SAEs and AESIs will be followed to resolution, to chronic stable state, or 
until the last subject visit for Part B occurs. At that time, any ongoing AEs will receive their 
final classification so that the safety database can be locked.   
A tabulation of all SAEs and AESIs, categorized by the Medical Dictionary for Regulatory 
Activities (MedDRA) preferred terms and assessed relationship to study drug , will be 
performed.  
3.5.7 Unsolicited Safety Measurements  
3.5.7.1  Adverse Events  
The investigator is responsible for reporting all AEs that are observed or reported during the 
study, regardless of their relationship to study drug or their clinical significance. If there is any doubt as to whether a clinical observation is an AE, the event should be reported. 
3.5.7.1.1  Definitions 
An AE is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Subjects will be instructed to record any AEs (solicited or unsolicited)  in the memory aid . 
A treatment -emergent AE is defined as any event not present before exposure to study drug or 
any event already present that worsens in intensity or frequency after exposure.  
A suspected adverse reaction  is any AE for which there is a reasonable possibility that the study 
drug caused the AE. For the purposes of investigational new drug safety reporting, “reasonable 
possibility ” means that there is evidence to suggest a causal relationship between the study 
drug a nd the AE. A suspected adverse reaction implies a lesser degree of certainty about 
causality than adverse reaction, which means any AE caused by a study drug.  An adverse 
reaction is any AE caused by a drug. Adverse reactions are a subset of all suspected adverse 
reactions for which there are reasons to conclude that the drug caused the event.  
An AE or suspected adverse reaction is considered “unexpected ” if it is not listed in the IB or 
at the specificity or severity that has been observed with the study dr ug being tested; or, if an 
IB is not required or available, is not consistent with the risk information described in the 
general investigational plan or elsewhere in the current application. For example, under this 
definition, hepatic necrosis would be une xpected (by virtue of greater severity) if the IB 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 66 referred only to elevated hepatic enzymes or hepatitis. Similarly, cerebral thromboembolism 
and cerebral vasculitis would be unexpected (by virtue of greater specificity) if the IB listed 
only cerebral vascular accidents. “Unexpected,” as used in this definition, also refers to AEs 
or suspected adverse reactions that are mentioned in the IB as occurring with a class of drugs 
or as anticipated from the pharmacological properties of the drug, but are not speci fically 
mentioned as occurring with the particular drug under investigation. 
Adverse events will also be evaluated by the investigator for the coexistence of any of the other 
following conditions: 
• Medically attended AE: an AE that leads to an unscheduled visit to a healthcare practitioner  
Any solicited AE that meets any of the following criteria will be entered onto the AE page of 
the eCRF : 
• Solicited local or systemic AE leading to the subject withdrawing from the study or the 
subject being withdrawn from the study by the investigator  
• Solicited local or sy stemic AE lasting beyond 7 days duration 
• Solicited local or systemic AE that lead to subject withdrawal from study drug  
• Solicited local or systemic AE that otherwise  meets the definition of an SAE 
3.5.7.1.2  Serious  Adverse Events  
An AE or suspected adverse reaction is considered “serious ” (SAE) if, in the view of either the 
investigator or Sponsor, it results in any of the following outcomes: 
• Death  
• Life-threatening AE  
• Inpatient hospitalization or prolongation of exist ing hospitalization  
• Persistent or significant incapacity or substantial disruption of the ability to conduct normal 
life functions 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 67 • Congenital anomaly or birth defect 
Important medical events that may not result in death, be life threatening, or require 
hospitalization may be considered serious when, based upon appropriate medical judgment, 
they may jeopardize the subject and may require medical or surgical intervention to prevent 
one of the outcomes listed in this definition. Examples of such medical events  include allergic 
bronchospasm requiring intensive treatment in an emergency room or at home, blood 
dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of 
drug dependency or drug abuse. 
An AE or suspected adverse reaction is considered “life threatening ” if, in the view of either 
the investigator or Sponsor , its occurrence places the subject at immediate risk of death. It does 
not include an AE or suspected adverse reaction that, had it occurred in a more severe form, 
might have caused death.  
3.5.7.1.3  Adverse Events of Special Interest  
Certain AESIs are evaluated after the administration of immunostimulatory agents. All subjects 
enrolled in the study will be monitored for AESIs from enrollment through the EOS visit. The occurrence of any of these AEs will be treated as an SAE, meeting the criterion of a “medically 
important event.” 
The list of AESIs is presented in  Appendix 2. 
A diagnosis of an AESI will be reported to the Sponsor in an expedited manner similar to  an 
SAE. The AESI diagnosis, as well as any medications taken to treat the condition, will be 
recorded in the subject ’s eCRF.  
3.5.7.1.4  Pregnancy  
The investigator is required to inform the Sponsor about any unexpected case of pregnancy 
occurring during the study (for female subjects as well as for partners of male subjects), 
monitor the pregnancy until delivery and report whatever outcome to the Sponsor (no later 
than 1 week after becoming aware of the pregnancy).  
Pregnancy report fo rms will be distributed to the study site to be used for this purpose. 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 68 The investigator must immediately (within 24 hours of awareness) report to the Sponsor any 
case of pregnancy resulting in an abnormal outcome (miscarriage or newborn with congenital 
abnormality and/or stillbirth) according to the procedures described for SAEs. 
 
3.5.7.2  Eliciting and Documenting Adverse Events  
The investigator is responsible for ensuring that all AEs and SAEs are recorded in the eCRF and reported to Moderna Therapeutics, Inc. In Part A of the study, AEs will be assessed from 
the time of the first dose administration at Visit 1 through Visit 7. However, for the time period 
after the ICF is signed until before receiving the study drug, AEs will only be recorded when 
they are defined  as one or more of the following: SAEs, AESIs, or AEs leading to study 
withdrawal. In Part B of the study, AESIs and SAEs will be assessed from Visit 8 through 
Visit 19. Any AEs occurring before receipt of the study drug will be analyzed separately from TEAEs.  
At every clinic visit or telephone contact , subjects will be asked a standard question to elicit 
any medically related changes in their well -being according to the scripts provided. Subjects  
will also be asked if they have been hospitalized, had any a ccidents, used any new medications, 
or changed concomitant medication regimens (both prescription and over -the-counter 
medications).  
In addition to subject observations, data from clinical laboratory test results, physical 
examination findings, or other documents relevant to subject safety classified as an AE will be 
documented on the AE page of the eCRF. 
3.5.7.3  Reporting Adverse Events  
All AEs reported or observed during the study will be recorded on the AE page of the eCRF. 
Information to be collected includes drug treatment and dose, type of event, time of onset, 
dosage, investigator -specified assessment of severity and relationship to study drug, time of 
resolution of the event, seriousness, as well as any required treatment or evaluations, and outcome. The AEs  resulting from concurrent illnesses, reactions to concurrent illnesses, 
reactions to concurrent medications, or progression of disease states must also be reported. All AEs will be followed until they are resolved or stable or judged by the investigator to be not clinically significant. The MedDRA will be used to code all AEs. 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 69 Any medical condition that is present at the time that the subject is screened but does not 
deteriorate should not be reported as an AE. However, if it deteriorates at any time durin g the 
study, it should be recorded as an AE. 
Any AE considered serious by the investigator or which meets SAE criteria (Section  3.5.7.1.2) 
must be reported to the Sponsor immediately ( within 24 hours of becoming aware of the SAE ). 
The investigator will assess whether there is a reasonable possibility that the study drug caused 
the SAE. The Sponsor will be responsible for notifying the relevant regulatory authorities of 
any SAE as outlined in the 21 US Code of Federal Regulations (CFR) Parts 312 and 320. The investigator is responsible for notifying the institutional review board  (IRB) directly.  
The following contact information is to be used for SAE reporting: 
SAE Hotline:  
SAE Fax line:  
3.5.7.4  Assessment of Severity  
The severity (or intensity) of an AE refers to the extent to which it affects the subject ’s daily 
activities and will be classified as mild (Grade 1), moderate (Grade 2),  severe (Grade 3), or 
potentially life threatening (Grade 4) using the following criteria:  
• Mild (Grade 1): These events do not interfere with the subject’ s daily activities.  
• Moderate (Grade 2): These events cause some interference with the subject ’s daily 
activities but do not require medical intervention.  
• Severe (Grade 3): These events prevent the subject ’s daily activity and require medical 
intervention. 
• Life threatening (Grade 4): These events require an emergency room visit or hospitalization.  
Changes in the severity of an AE should be documented to allow an assessment of the duration 
of the event at each level of intensity to be performed. An AE characterized as intermittent 
requires documentation of onset and duration of each episode. 
The Toxicity Grading Scale for Healthy Adult and Adolescent V olunteers Enrolled in 
Preventative Vaccine Clinical Trials ( CBER 2007) will be used to categorize solicited 
PPD
PPD
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 70 reactogenicity, safety laboratory test results, and vital sign measurements observed during this 
study. Specific criteria for clinical and laboratory abnormalities are presented in Table  6-3 and 
Table  6-4, respectively , and will be graded if outside of the reference range for the laboratory 
utilized. Of note, the laboratory test value i tself may not be the AE classification. Each AE will 
be classified by its most specific term (eg, renal insufficiency, bronchitis) and supporting 
evidence (eg, laboratory test value, x -ray) will not be classified as an AE per se.  
3.5.7.5  Assessment of Causality  
The investigator ’s assessment of an AE ’s relationship to study drug is part of the 
documentation process but is not a factor in determining what is or is not reported in the study.  
The investigator will assess causality (ie, whether there is a reasonable pos sibility that the study 
drug caused the event) for all AEs and SAEs. The relationship will be characterized using the 
following classification: 
• Not related: There is not a reasonable possibility of Sponsor's product relationship: Subject 
did not receive the Sponsor’ s product OR temporal sequence of the AE onset relative to 
administration of the Sponsor’ s product is not reasonable OR the AE is more likely 
explained by another cause than the Sponsor’ s product.  
• Related: There is a reasonable possibility of Sponsor’ s product relationship: There is 
evidence of exposure to the Sponsor’ s product. The temporal sequence of the AE onset 
relative to the administration of the Sponsor’ s product is reasonable. The AE is more likely 
explained by the Sponsor’s product than by another cause. 
3.5.7.6  Follow -Up of Adverse Events 
All AEs must be reported in detail on the appropriate page of the eCRF and followed until the 
AE is resolved or stable or judged by the investigator to be not clinically significant in Part A 
of the study. For Part B of the study, only AESIs and SAEs will be recorded . The investigator 
may request an  unscheduled visit at any time , if warranted.  
3.5.8 Clinical Laboratory Testing  
Clinical laboratory tests will be performed by the central laboratory , unless specified otherwise . 
Blood and urine will be collected in Part  A at the time points indicated in the schedule of events 
(Table  6-1). Fasting is not required before collection of laboratory samples. 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 71 The following hematology, serum chemistry, coagulation, and urinalysi s assessments will be 
performed. The results will be toxicity graded using Table  6-4. 
Hematology:  Hematocrit, hemoglobin, mean corpuscular hemoglobin, mean corpuscular 
hemoglobin concentration, mean corpu scular volume, platelet count, red 
blood cell count, and total and differential leukocyte count 
Serum 
Chemistry:  Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, 
amylase, lipase, bilirubin (total and direct ), blood urea nitrogen, creatinine, 
random glucose, potassium, sodium, total protein, albumin, and calcium 
Females subjects only: β-human chorionic gonadotropin (childbearing 
potential) and follicle -stimulating hormone (post-menopausal) 
Coagulation : Prothrombin time, p artial thromboplastin time  
Urinalysis:  pH, protein, glucose, ketone, bilirubin, urobilinogen, blood, nitrite, 
leucocytes, and specific gravity  
A pregnancy test ( β-human chorionic gonadotropin) will be performed on all female subjects 
who have reproductive potential at Screening and before each dose administration (urine or 
serum). Only pregnancy tests at Screening and for unscheduled visits will be sent to the cent ral 
laboratory. P regnancy test ing prior to each study vaccination will be performed by the local 
laboratory . A follicle -stimulating hormone test will be performed at Screening, as necessary, to 
confirm post -menopausal status in female subjects, if not documented in the subject ’s medical 
records . 
Human immunodeficiency virus (types 1 or 2) antibody, hepatitis B surface antigen, and 
hepatitis  C virus antibody will be assessed at Screening. 
A urine screen for drugs of abuse will be performed by the local labor atory  at Screening for 
alcohol, opiates, cocaine, phencyclidine, amphetamines, benzodiazepines, and methadone.  
Should safety la boratory testing result in a Grade 2 or higher toxicity, repeat testing must occur 
within the next 10 days ; this may include an unscheduled visit. Should the subject ’s laboratory 
value not return to baseline then periodic testing may be needed until the abnormality is 
deemed to be associated with a new stable AE or determined to be not clinically significant by 
the investigator.  
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 72 Those values that fall within the normal range of the laboratory will automatically be classified 
as normal. All values that have  a toxicity of Grade 1 or higher will also be evaluated by the 
investigator and classified as “abnormal clinically significant ( CS)”, or “abnormal not 
clinically significant (NCS) ”. Investigators should use their clinical judgment when 
considering the clinical significance of any abnormal laboratory findings . All laboratory test 
values with a toxicity  of Grade 3 or higher will be entered as AEs . Any additional laboratory 
test value that is determined to be clinically significant will also be recorded as an AE, should 
that be considered the primary diagnosis. In such instances, the abnormal value and grade will be documented on the AE page of the eCRF. The investigator will continue to monitor the 
subject with additional assessments until the values have reached the reference range or the 
values at Screening or until the investigator determines that follow -up is no longer me dically 
necessary. The only exception to this rule would be a laboratory test value that is associated with an identified ongoing AE where that event would be the classifying AE. 
3.5.9 Vital Sign Measurements 
Vital sign measurements will include systolic and dia stolic blood pressures, heart rate, 
respiratory rate, and body temperature (which is classified as a solicited systemic event). The 
subject will be seated for at least 5  minutes before all measurements are taken. Vital signs will 
be measured in Part  A at t he time points indicated in the schedule of events ( Table  6-1).  
When procedures overlap and are scheduled to occur at the same time point, the order  of 
procedures should be vital sign measurements and then the blood collection. 
Of note, on the day of vaccination, if a subject is noted to have a systolic or diastolic blood 
pressure, heart rate, or respiratory rate measurement that shows Grade 2 or higher toxicity after 
2 measurements (even after relaxing or resting) ; has an acute illness ; or has an oral temperature 
>38°C, the subject  should not receive a vaccination on that day and will need to return on 
subsequent days for their vaccination.  
If any of the vital sign measurements meet the toxicity grading criteria for clinical 
abnormalities ( Table  6-3) of Grade 3 or higher , the abnormal value  and grade will be 
documented on the AE page of the eCRF (unless there is another known cause of the 
abnormality and that would result in an AE classification). The investigator will continue to 
monitor the subject with additional assessments until the value has reached the reference range, 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 73 the value at Screening, is considered stable, or until the investigator determines that follow -up 
is no longer medically necessary.  
3.5.10  Physical Examinations  
In Part  A, a full physical examination will be performed at Screen ing and a symptom -directed 
(targeted) physical examination will be performed at all other scheduled time points indicated 
in the schedule of events (Table  6-1). The full examination will include assessment of skin, 
head, ears, eyes, nose, throat, neck, thyroid, lungs, heart, cardiovascular, abdomen, lymph 
nodes, and musculoskeletal system/extremities. Interim physical examinations will be performed at t he discretion of the investigator, if necessary, to evaluate AEs or clinical 
laboratory abnormalities.  Prior to vaccination and at 7 days following vaccination, a physical 
evaluation of the arm that was vaccinated and the associated lymph nodes should be e valuated.  
Height and weight will be measured and body mass index will be calculated at Screening only.  
3.6 Statistical Analysis Plans  
3.6.1 Safety  Endpoints  
The following are the safety (primary) endpoints: 
Part A:  
• Solicited AEs (local and systemic reactogenicity events) collected for 7 days following 
each vaccination with toxicity grading 
• Unsolicited AEs collected for 28 days following each vaccination; a dditional classification 
if serious, medically attended, or an AESI  
• Safety laboratory test results  (serum chemistry, hematology, coagulation, and urinalysis) 
with toxicity grading  
• Vital sign measurements with toxicity grading and physical examination findings  
Part B:  
• Serious AEs  and AESIs through 1 year  (or until re solved, whichever comes first ) following 
the last vaccination  
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 74 3.6.2 Immunogenicity Endpoints  
The immunogenicity assessments are as follows:  
Part A: 
• Neutralizing serum antibody titers to CHIKV proteins (baseline  and 28 days after each 
vaccination ) 
• Serum antibody titers (IgG) to CHIKV proteins (baseline and 28 days after each 
vaccination ) 
• Exploratory antibody assays may be performed with excess serum to assess for 
cross -reactivity to related viruses at the discretion of the Sponsor 
• Additional explorat ory assays based upon current research may be performed with excess 
serum to better characterize the immune response to the CHIKV proteins at the discretion 
of the Sponsor 
Part B  
• Neutralizing serum antibody titers to CHIKV ( at 6 and 12 months  after the last vaccination)  
• Serum binding antibody titers (IgG) to CHIKV- specific proteins (at 6 and 12 months after 
the last vaccination)  
• Exploratory antibody assay s may be performed with excess serum to assess for 
cross -reactivity  to related viruses  at the discretion of the Sponsor  
• Additional exploratory assays based upon current research may be performed with excess 
serum to better characterize the immune response to the CHIKV protein s at the discretion 
of the Sponsor 
3.6.3 Sample Size Calculations  
Approximately 60 subjects are planned to be randomized, 20 per dose level. Formal sample 
size calculations were not performed as this is an observational safety and immunogenicity 
study with no formal null hypotheses being tested. 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 75 3.6.4 Analysis Sets 
The All Enrolled  Subjects set will include subjects who signed the ICF. The All Enrolled 
Subjects set will only be used for descriptive purposes.  
The Safety set will include all subjects who receive at least 1  dose of study drug ( VA L -181388 
or placebo).  All subjects in the Safety set will be analyzed according to the study drug actually 
received and not according to the study drug the subject was random ly assigned  to receive, in 
the event there is a discrepancy.  
The Per -Protocol set will include all subjects who did not observe a major protocol violation, 
received vaccine within the acceptable vaccination window (their full dose(s) of assigned study 
drug), had blood collection within accepted visit windows, and had a pre- vaccination and at 
least one serum sample from the p ost-vaccination testing period available for testing. All 
subjects in the Per -Protocol set will be analyzed according to the study  drug the subject was 
randomly assigned to receive and not according to what was actually received, in the event 
there is a discrepancy. In the case where there is not a paired sample for the specific time point 
that data will not be included in the analysis.  
The Intent -to-Treat set will provide supportive analyses. For the Intent -to-Treat set, all subject s 
who were random ly assigned to the study will be included regardless of protocol violations, 
exceeded visit windows, missed vaccination, or missing data.  
3.6.5 Statistical Analysis  
Details of all statistical analyses will be described in a statistical analysis plan. All data 
collected will be presented in data listings. Data from subjects excluded from an analysis 
population will be presented in the data listings but not included in the calculation of summary 
statistics.  
Data from subjects receiving placebo will be pooled across dose level cohorts for all 
presentations. 
For categorical variables, frequencies and percentages will be presented. Continuous variables 
will be summarized using descriptive  statistics (number of subjects, mean, median, SD, 
minimum, and maximum).  
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 76 3.6.5.1  Immunogenicity  Analys es 
The following immunogenicity outcome measures (for serum neutralizing antibody titers and 
serum binding antibody titers to CHIKV -specific proteins) and their 95% confidence intervals, 
where appropriate, will be summarized by dose level cohort and combined placebo, and by 
days post- vaccination:  
• Geometric mean titer (GMT) at baseline (pre -vaccination at Visit 1 ) and at post -dose time 
points  
• Geometric mean ratio Post/Pre: the ratio of post -vaccination GMT to pre-vaccination  (Visit 1) 
GMT of subjects who have a baseline sample and post -vaccination results at post -dose time 
points  
• Seroresponse : The proportion of subjects in each treatment group who either had an 
undetectable titer at baseline and detectable titer after vaccination, or detectable titer at baseline and at least a 4 -fold increase (of baseline titer) after vacci nation will be calculated  
3.6.5.2  Safety Analyses  
Data for subjects receiving placebo will be pooled across all dose levels for all presentations . 
Reactogenicity will be summarized by dose level s (25, 50, or 100 µg or placebo), vaccination 
(first or second), duration, relationship to study vaccine , and severity. Adverse events will be 
coded by preferred term and system organ class using MedDRA  and summarized by part, 
treatment , vaccination (first or second), and overall. Adverse events will also be summarized 
by severity and relationship to study vaccine. Descriptive statistics will be presented and the 
difference in the proportion of AEs will be provided comparing each dose level with placebo recipients pooled across all dose levels . Adverse events for s ubjects in the safety cohort for 
each dose level will  be provided in a separate subject listing. Adverse events leading to 
withdrawal, AESIs, medically attended AEs, and SAEs will be provided by subject in a listing.  
Safety data from clinical laboratory test results  and vital sign measurements will be graded  by 
severity and analyzed by treatment group and vaccination (first or second). Absolute and 
change from baseline values will be provided according to the toxicity table, along with mean, 
median, and standard deviation. Results of hematology, serum chemistry, coagulation, and 
urinalysis assessments; urine drug screen; and pregnancy testing will be listed for all subjects 
randomly assigned to receive study treatment . 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 77 Medical history data for all subjects randomly assigned to receive study treatment will be 
presented by subject in a listing.  
Baseline demographic and background variables will be summarized by treatment group and 
cohort for all subjects. The number of subjects who enroll in the study and the number and percentage of subjects who complete the study will be presented. Frequency and percentage of 
subjects who withdraw or discontinue from the study, and the reason for withdrawal or discontinuation, will also be summarized.  
Prior and concomitant medication will be listed (with start and stop dates)  for each subject and 
summarized by common medical dictionary coding. Any vaccinations that occur during the 
trial conduct will also be captured and summarized. 
3.6.6 Handling of Missing Data  
For GMT calculation, antibody values reported as below the lower limit  of quantification 
(LLOQ) will be replaced by 0.5 × LLOQ. For fold- rise, values <LLOQ will be replaced by 
0.5 × LLOQ . Values that are greater than the upper limit of quantification (ULOQ) will be 
converted to the ULOQ. Missing results will not be imputed. 
3.6.7 Interim Analyses  
Following completion of each dose level cohort in Part A, the database will be locked for that 
cohort and safety and/or immune testing results through 28 days following the final vaccination 
will be analyzed. As dose escalation occurs, cumulative analyses will be included for each 
subsequent data lock to allow for all prior dos e level  cohorts to be analyzed by dose level  and 
in aggregate for V AL -181388 exposure. Immunogenicity and safety data, including mean 
group analyses of change from ba seline, where applicable, will be summarized for each dose 
level cohort and combined placebo group. These analyses will be performed by an unblinded 
team, independent of the study team. All study personnel and participants other than the 
third -party statistician will remain blinded to treatment allocation. These data will be provided 
to designated Sponsor representatives only. They will inform decisions on this and other 
development programs using the same mRNA platform.  
An interim analysis of  safety, reactogenicity , and immunogenicity data collected from Day 1 
to Month 7 will be conducted and will be reported on a treatment assignment level . Access to 
individual listings will be restricted  to identified Sponsor  members  and the contract research 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 78 organization unblinded statistician . Study sites will remain blinded. This analysis will provide 
information regarding short -term antibody persistence . The final analysis of safety and 
immunogenicity data collected from Visit Day 1  through the end of the  study will be performed 
as soon as data are cleaned and locked. The results of this analysis will be presented in a clinical 
study report  including i ndividual data listings . 
Additional information can be found in the statistical analysis plan. 
3.7 Data Qualit y Assurance  
All aspects of the study will be monitored for compliance with applicable government 
regulations with respect to current ICH harmonised tripartite guideline E6(R1): Good Clinical 
Practice and current standard operating procedures. The eCRFs will be utilized and accessed 
through iMedidata® via the internet. This electronic data capture system is validated and 
compliant with US Title 21 of CFR Part 11. Each person involved with the study will have an 
individual identification code and password tha t allow for record traceability. There may be an 
internal quality review audit of the data and additional reviews by the clinical monitor. 
Due to safety review requirements, no more than 3 business days should transpire between 
subject data availability (v isits, laboratory test results, etc) and data entry. As a quality measure, 
timeliness of data entry and data query resolution will be reported to the IST. Other issues of data quality that may hinder safety review or pose a concern with patient safety will  also be 
reported to the IST with appropriate awareness to the SMC if needed. 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 79 4 Investigator Obligations  
The following administrative items are meant to guide the investigator in the conduct of the 
study and may be subject to change based on industry and government standard operating 
procedures, working practice documents, or guidelines. Changes will be reported to the IRB but will not result in protocol amendments. 
4.1 Confidentiality  
All laboratory specimens, e valuation forms, reports, and other records will be identified in a 
manner designed to maintain subject confidentiality. All records will be kept in a secure storage 
area with limited access. Clinical information will not be released without the written 
permission of the subject, except as necessary for monitoring and auditing by the Sponsor , its 
designee, relevant regulatory authority, or the IRB. 
The investigator and all employees and coworkers involved with this study may not disclose 
or use for any purpose other than performance of the study, any data, record, or other 
unpublished, confidential information disclosed to those individuals for the purpose of the study. Prior written agreement from the Sponsor or its designee must be obtained for the 
disclosure of any said confidential information to other parties. 
4.2 Institutional Review  
Federal regulations and the ICH E6(R1) guidelines require that approval be obtained from an IRB before participation of human subjects in research studies. Before study onset, the protocol, informed consent, advertisements to be used for the recruitment of study subjects, and any 
other written information regarding this study to be provided to the subject must be approved 
by the IRB. Documentation of all IRB approvals and of the  IRB compliance with the ICH 
E6(R1) guidelines will be maintained by the site and will be available for review by the 
Sponsor or its designee. 
All IRB approvals should be signed by the IRB chairman or designee and must identify the 
IRB name and address, th e clinical protocol by title or protocol number or both and the date 
approval or a favorable opinion was granted. 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 80 4.3 Subject Consent  
Written informed consent in compliance with US Title 21 CFR Part 50 shall be obtained from 
each subject before he or she enter s the study or before any unusual or non -routine procedure 
that involves risk to the subject are performed. If any institution -specific modifications to 
study- related procedures are proposed or made by the site, the consent should be reviewed by 
the Sponsor or its designee or both before IRB submission. Once reviewed, the investigator 
will submit the ICF to the IRB for review and approval before the start of the study. If the ICF is revised during the course of the study, all active participating subjects must sign the revised form.  
Before recruitment and enrollment, each prospective subject will be given a full explanation of the study and be allowed to read the approved ICF. Once the investigator is assured that the subject understands the implications of participating in the study, the subject will be asked to 
give his or her consent to participate in the study by signing the ICF. A separate counseling and 
consent for HIV testing will occur.  
The ICF will also explain that  excess  serum from immunogenicity testing may be used for 
future research which may be performed at the discretion of the Sponsor to better characterize 
the immune response to the  CHIKV protein (inclusive of additional assay development and the 
immune response across alphaviruses and flaviviruses) .  
The investigator or designee will provide a copy of the ICF to the subject. The original form shall be maintained in the subject’ s medical records at the  site.  
4.4 Study Reporting Requirements  
By participating in this study , the investigator agrees to submit reports of SAEs and AESIs 
according to the time line and method outlined in this protocol. In addition, the investigator agrees to submit annual reports to his or her IRB as appropriate. 
4.5 Financial Disclosure and Obligatio ns 
The investigator is required to provide financial disclosure information to allow the Sponsor 
to submit the complete and accurate certification or disclosure statements required under 
21 CFR 54. In addition, the investigator must provide to the Sponsor a commitment to 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 81 promptly update this information if any relevant changes occur during the course of the 
investigation and for 1 year following the completion of the study. 
Neither the Sponsor , PPD, nor the study site is financially responsible for further testing or 
treatment of any medical condition that may be detected during the screening process. In 
addition, in the absence of specific arrangements, neither the Sponsor, PPD, nor the study site 
is financially responsible for further treatment of the dise ase under study.  
4.6 Investigator Documentation  
Prior to beginning the study, the investigator will be asked to comply with ICH E6(R1) 8.2 and 
Title 21  of the CFR by providing the following essential documents, including but not limited 
to: 
• IRB approval, 
• An or iginal investigator -signed investigator agreement page of the protocol, 
• Form FDA 1572, fully executed, and all updates o n a new fully executed Form FDA  1572, 
• Curriculum vitae for the principal investigator and each sub- investigator listed on 
Form  FDA 1572. Current licensure must be noted on the curriculum vitae. The curriculum 
vitae will be signed and dated by the principal investigators and subinvestigators at study 
start-up, indicating that they are accurate and current,  
• Financial disclosure information to allow the Sponsor to submit complete and accurate 
certification or disclosure statements  required under 21 CFR 54. In addition, the 
investigators must provide to the Sponsor a commitment to promptly update this 
information if any relevant changes occur during the course of the investigation and for 1 year aft er the completion of the study, 
• An IRB -approved ICF, samples of site advertisements for recruitment for this study, and 
any other written information about this study that is to be provided to the subject, and  
• Laboratory certifications and reference ranges for any local laboratories used by the site, 
in accordance with 42 CFR 493. 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 82 4.7 Study Conduct  
The investigator agrees that the study will be conducted according to the principles of 
ICH E6(R1). The investigator will conduct all aspects of this study in accordance with all 
national, state, and local laws or regulations. The study will be conducted i n compliance with 
the protocol, current Good Clinical Practice guidelines – adopting the principles of the 
Declaration of Helsinki – and all applicable regulatory requirements. 
4.8 Data Collection  
4.8.1 Case Report Forms and Source Documents  
As part of the responsibilities assumed by participating in the study, the investigator agrees to maintain adequate case histories for subjects treated as part of the research under this protocol. The investigator agrees to maintain accurate eCRFs and source documentation as part  of the 
case histories. These source documents may include laboratory reports and similar sources. 
Electronic case report forms are accessed through iMedidata
® via the internet. This electronic 
data capture system is validated and compliant with 21 CFR 11. Each person involved with the 
study will have an individual identification code and password that allows for record 
traceability. Thus, the system, and subsequently any investigative reviews, can identify 
coordinators, investigators, and individuals who h ave entered or modified records, as well as 
the time and date of any modifications. There may be internal quality review audit of the data 
and additional reviews by the clinical monitor.  
Each eCRF is presented as an electronic copy, allowing data entry by site personnel, who can 
add and edit data, add new subjects, identify and resolve discrepancies, and view records. This system provides immediate direct data transfer to the database, as well as immediate detection of discrepancies, enabling site coordinators to resolve and manage discrepancies in a timely 
manner.  
4.9 Adherence to Protocol  
The investigator agrees to conduct the study as outlined in this protocol in accordance with 
ICH E6(R1) and all applicable guidelines and regulations. 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 83 4.10 Reporting Adverse Event s 
By participating in this study , the investigator agrees to submit reports of SAEs according to 
the time line and method outlined in this protocol. In addition, the investigator agrees to submit 
annual reports to his IRB as appropriate. The investigator also agrees to provide the Sponsor 
with an adequate report, if applicable, shortly after completion of the investigator ’s 
participation in the study.  
4.11 Investigator ’s Final Report  
Upon completion of the study, the investigator, where applicable, should inform the institution; 
the investigator/institution should provide the IRB with a summary of the study ’s outcome, 
and the Sponsor and regulatory authority(ies) with any reports requi red. 
4.12 Records Retention  
Essential documents should be retained until at least 2 years after the last approval of a marketing application in an ICH region and until there are no pending or contemplated 
marketing applications in an ICH region or at least 2 ye ars have elapsed since the formal 
discontinuation of clinical development of the study drug . These documents should be retained 
for a longer period, however, if required by the applicable regulatory requirements or by an 
agreement with the Sponsor . It is the Sponsor’ s responsibility to inform the 
investigator/institution as to when these documents no longer need to be retained. 
4.13 Publications  
After interim analyses or at completion of the study, the data may be considered for reporting 
at a scientific meeting  or for publication in a scientific journal. In these cases, the Sponsor will 
be responsible for these activities and will work with the investigators to determine how the 
manuscript is written and edited, the number and order of authors, the publication to which it 
will be submitted, and other related issues. The Sponsor has final approval authority over all 
such issues.   
Data are the property of the Sponsor and cannot be published without their prior authorization, 
but data and publication thereof will not be unduly withheld. 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 84 5 Study Management  
5.1 Monitoring  
5.1.1 Monitoring of the Study  
The clinical monitor, as a representative of the Sponsor , is obligated to follow the study closely. 
In doing so, the monitor will visit the investigator and study facility at periodic intervals, in 
addition to maintaining necessary telephone and letter contact. The monitor will maintain current personal knowledge of the study through observation, review of study records and source documentation, and discussion of the conduct of the study with the investigator and 
staff.  The monitor will be blinded to treatment assignment.  A separate unblinded study monitor 
will be responsible for drug accountability. 
All aspects of the study will be carefully monitored by the Sponsor or its designee for 
compliance with applicable government regulation with respect to current ICH E6(R1) 
guidelines and standard operating procedures. 
5.1.2 Inspection of Records  
The investigator and institution involved in the study will permit study -related mo nitoring, 
audits, IRB review, and regulatory inspections by providing direct access to all study records. In the event of an audit, the investigator agrees to allow the Sponsor , their representatives, the 
FDA, the Department of Defense or federal represent atives, or other regulatory agenc ies access 
to all study records. 
The investigator should promptly notify the Sponsor of any audits scheduled by any regulatory 
authorities and promptly forward copies of any audit reports received to the Sponsor. 
5.2 Management  of Protocol Amendments and Deviations  
5.2.1 Modification of the Protocol  
Any changes in this research activity, except those necessary to remove an apparent, immediate 
hazard to the subject, must be reviewed and approved by the Sponsor or designee. Amendments 
to the protocol must be submitted in writing to the investigator ’s IRB for approval before 
subjects are enrolled into an amended protocol. 
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 85 5.2.2 Protocol Violations and Deviations  
The investigator or designee must document and explain in the subject ’s source documentation 
any deviation from the approved protocol. The investigator may implement a deviation from, 
or a change to, the protocol to eliminate an immediate hazard to study subjects without prior IRB approval. As soon as possible after such an occurrence, the implemented deviation or 
change, the reasons for it, and any proposed protocol amendments should be submitted to the 
IRB for review and approval, to the Sponsor for agreement, and to the regulatory authorities, 
if required.  
A deviation from the protocol  is an unintended or unanticipated departure from the procedures 
or processes approved by the Sponsor and the IRB and agreed to by the investigator. Deviations 
usually have an impact on individual subjects or a small group of subjects and do not involve inclusion/exclusion or primary endpoint criteria. A protocol violation occurs when the subject 
or investigator do not adhere to the protocol, resulting in a significant, additional risk to the subject. Protocol violations can include non- adherence to inclusi on or exclusion criteria, 
enrollment of the subject without prior Sponsor approval, or non- adherence to FDA regulations 
or ICH E6(R1) guidelines. 
Protocol violations and deviations will be documented by the clinical monitor throughout the 
course of monitor ing visits. The investigator will be notified in writing by the monitor of 
violations and deviations. The IRB should be notified of all protocol violations and deviations, if appropriate, in a timely manner. 
5.3 Study Termination  
Although the Sponsor has every  intention of completing the study, they reserve the right to 
discontinue it at any time for clinical or administrative reasons.  
The end of the study is defined as the date on which the last subject completes the last visit 
(includes the EOS visit and any additional long- term follow -up). Any additional long -term 
follow- up that is required to monitor the resolution of a finding or AE may be reported through 
an amendment to the clinical study report.  
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 86 5.4 Final Report  
Whether the study is completed or prematurely terminated, the Sponsor will ensure that clinical 
study reports are prepared and provided to the regulatory agency(ies) as required by the 
applicable regulatory requirement(s). The Sponsor will also ensure that clinical study reports 
in marketing applications meet the standards of the ICH harmonised tripartite guideline E3: 
Structure and content of clinical study reports.  
Where required by applicable regulatory requirements, an investigator signatory will be 
identified for the approval of the clinical study report. The investigator will be provided reasonable access to statistical tables, figures, and relevant reports and have the opportunity to 
review complete study results.  
A final clinic al study report will contain all data collected through  28 days following the second 
vaccination of all dosing cohorts (Part  A) and all data  through the extension safety period 
(12-month follow -up after the second vaccination ) and will include additional information on 
immune persistence.  
Upon completion of the clinical study report (s), the Sponsor will provide the investigator (s) 
with the final approved clinical study report (s).  
Moderna Therapeut ics, Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3  
 Page 87 6 Appendices  
6.1 Appendix  1: Schedule  of Events  
The schedule of events for Part A is presented in Table  6-1, and the schedule of events for 
Part B is presented in Table  6-2. 
 
Moderna Therapeutics , Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3 
 Page 88 Table  6-1 Part A Schedule of Events  
Moderna Therapeutics , Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3 
 Page 89 Procedure Screening  Treatment Period  
Study visit  0 1 1aa 1ba 2 3 3aa 4 5 6 7 
Vaccination day   X      X    
Days relative to most recent vaccination  NA 0 1 2 7 17 21 28 7 17 28 
Window allowance  +28 0 0 0 +3 ±3 +3 +7 +3 ±3 +7 
Informed consent  X           
Inclusion/Exclusion criteria  X           
Medical history X           
Physical examinationb X Xc   X  X Xc X  X 
Vital sign measurementsd X Xe X X X  X Xe X  X 
Serologyf X           
Clinical laboratory testing Xg Xc,g   Xg Xh Xh Xc,g Xg Xh Xh 
Urine drug screeni X           
Pregnancy test (all female subjects of childbearing 
potential) X Xc      Xc    
Follicle -stimulating hormone (female subjects only)j X           
Randomization   X          
Blood sample for serum neutralizing antibody titersk  Xc      Xc   X 
Blood sample for serum antibody titers to CHIKV 
proteink  Xc      Xc   X 
Blood sample for exploratory antibody assayk  Xc      Xc   X 
Study drug administration  X      X    
Reactogenicity   Xe X X X  X Xe X  X 
Subject memory aid completion: solicited local and systemic AEs, oral body temperature, and 
medications taken
l  X 
Visit 1 through Visit 2   X 
Visit 4 through 
Visit 5   
Moderna Therapeutics , Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3 
 Page 90 Procedure Screening  Treatment Period  
Study visit  0 1 1aa 1ba 2 3 3aa 4 5 6 7 
Vaccination day   X      X    
Days relative to most recent vaccination  NA 0 1 2 7 17 21 28 7 17 28 
Window allowance  +28 0 0 0 +3 ±3 +3 +7 +3 ±3 +7 
Subject memory aid completion: any unsolicited 
AEs and related medicationsl  X  
(Visit 1 through Visit 7) 
Collection of memory aids         X   X 
Adverse events assessmentm X X X X X X X X X X X 
Prior and concomitant medicationsn X X X X X X X X X X X 
Abbreviations: AE, adverse event; CHIKV, chikungunya virus;  NA, not applicable . 
a. This visit is required for sentinel safety group  subjects only.  
b. Full physical examination at Screening; symptom- directed (targeted) physical examination at all other scheduled time points. Interim physical examinations 
will be performed at the discretion of the investigator, if necessary. Height and weight will be measured and body mass index calculated at Screening only.  
c. Assessment to be performed before study drug administration.  
d. Vital sign measurements (systolic and diastolic blood pressures, heart rate, respiratory rate, and body temperature) on Visits 1 and 4 will be collected once 
before study drug  administration and at least 1 hour after study drug  administration (before subjects are discharged).  Vaccination cannot occur if systolic or 
diastolic blood pressure, heart rate, or respiratory rate  measurements  show Grade 2 or higher  toxicity after 2 measurements ; if a subject has an acute illness ; 
or if a subject has an oral temperature >38°C . 
e. Assessment to be performed before and after study drug administration.  
f. Serology testing will include hepatitis B surface antigen, hepatitis C virus antibody, and human immunodeficiency virus type  1 and 2 antibodies.  
g. Hematology, serum chemistry, coagulation, and urinalysis assessments.  
h. Safety laboratory tests for albumin, bilirubin (total and direct), prothrombin time, partia l thromboplastin time, alkaline phosphatase, alanine aminotransferase, 
aspartate aminotransferase.  
i. The drug screen will include alcohol, opiates, cocaine, phencyclidine, amphetamines, benzodiazepines, and methadone. 
j. To confirm post -menopausal status, as needed.  
k. Excess serum from immunogenicity may be used for future research  at the discretion of the Sponsor  to better characterize the immune response to the CHIKV 
protein . 
l. Subjects will be instructed on how to complete  the memory aid  prior to discharge from t he clinic  at Visit 1 . Subjects will be instructed to call or return to the 
clinic within 24 hours if reactogenicity reaches Grade 3 or highe r during the first 7 days following vaccination.  
Moderna Therapeutics , Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3 
 Page 91 m. Adverse events will be assessed from the time of study drug  administration on Visit  1 through Visit 7. However, for the time period after the informed consent 
form  is signed until before receiving the study drug, AEs will only be recorded when they are defined as one or more of the following: serious AEs, AEs of 
special interest , AEs leading to study withdrawal. 
n. Prior medications taken by the subject within the 30 days before providing informed consent will be collected. Concomitant medications include all  
medications (including vaccinations outside of the trial ) taken by the subject from the time of signing the informed consent and through Visit  7. 
Moderna Therapeutics , Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3 
 Page 92 Table  6-2 Part B Schedule of Events  
Procedure             
Study visit 8 9 10 11 12 13 14 15 16 17 18 19a 
Study day from  1st dose, if 2nd dose not completed  84 112 140 168 196 224 252 280 308 336 364 392 
Study day from 2nd dose, if completed  56 84 112 140 168 196 224 252 280 308 336 364 
Window allowance  ±7 ±7 ±7 ±7 ±15 ±7 ±7 ±7 ±7 ±7 ±7 +15 
Type of visit SC SC SC SC LVb SC SC SC SC SC SC LVb 
Safety contactc X X X X  X X X X X X  
Blood sample for serum neutralizing antibody titersd     X       X 
Blood sample for serum antibody titers to CHIKV proteinsd     X       X 
Blood sample for exploratory antibody assaysd     X       X 
Adverse events assessmente X X X X X X X X X X X X 
Concomitant medicationsf X X X X X X X X X X X X 
Abbreviations: CHIKV, chikungunya virus; LV, laboratory  visit; SC; safety contact . 
a Visit 19 will be considered the end of study  visit.  
b Blood samples for immune persistence will be collected from each subject using a method that maintains the blind (eg, home visits, locally contracted 
laboratories).  
c Each safety contact will occur by telemedicine (eg, telephone, text message, internet).  
d Exces s serum from immunogenicity may be used for future research at the discretion of the Sponsor to better characterize the immune response to the 
CHIKV protein and/or to assess for cross -reactive antibody responses to other related viruses.  
e Each safety contact will capture outcomes of any adverse event of special interest  or serious adverse event that remains unresolved since the last visit or is 
newly identified through scripted query. Additional data may be requested through medically attended visits, and medications and vaccination will be 
recorded as part of the medical intake for each telemedicine visit.  
f Receipt of immunomodulators (including vaccines), immunosuppressants, other concomitant medications that could potentially impact immune response  
will be collected through Visit 19. 
Moderna Therapeutics , Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3 
 Page 93 6.2 Appendix  2: Adver se Events of Special Interest  
The following is a list of Adverse Events of Specia l Interest:  
Gastrointestinal disorders: 
• Celiac disease  
• Crohn’ s disease  
• Ulcerative colitis  
• Ulcerative proctitis  
Liver disorders: • Autoimmune cholangitis  
• Autoimmune hepatitis  
• Primary biliary cirrhosis  
• Primary sclerosing cholangitis  
Metabolic diseases:  
• Addison’ s disease  
• Autoimmune thyroiditis (including Hashimoto thyroiditis)  
• Diabetes mellitus type I  
• Grave's or Basedow ’s disease  
Musculoskeletal disorders: • Antisynthetase syndrome 
• Dermatomyositis  
Moderna Therapeutics , Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3 
 Page 94 • Juvenile chronic arthritis (including Still’ s disease)  
• Mixed  connective tissue disorder 
• Polymyalgia rheumatic  
• Polymyositis  
• Psoriatic arthropathy  
• Relapsing polychondritis 
• Rheumatoid arthritis  
• Scleroderma, including diffuse systemic form and CREST syndrome 
• Spondyloarthritis, including ankylosing spondylitis, reactive  arthritis (Reiter's Syndrome) 
and undifferentiated spondyloarthritis 
• Systemic lupus erythematosus  
• Systemic sclerosis  
Neuro -inflammatory disorders:  
• Acute disseminated encephalomyelitis, including site specific variants (eg,  non-infectious 
encephalitis, encephalomyelitis, myelitis, myeloradiculomyelitis)  
• Cranial nerve disorders, including paralyses/paresis (eg, Bell’ s palsy)  
• Guillain -Barré syndrome, including Miller Fisher syndrome and other variants 
• Immune- mediated peripheral neuropathies and plexopathies, including chronic 
inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, and 
polyneuropathies associated with monoclonal gammopathy 
• Multiple sclerosis  
• Narcolepsy  
Moderna Therapeutics , Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3 
 Page 95 • Optic neuritis  
• Transverse myelitis  
Skin disorders: 
• Alopecia areata  
• Autoimmune bullous skin diseases, including pemphigus, pemphigoid and dermatitis 
herpetiformis  
• Cutaneous lupus erythematosus 
• Erythema nodosum 
• Morphoea 
• Lichen planus 
• Psoriasis 
• Sweet ’s syndrome 
• Vitiligo  
Vasculitides: • Large vessels vasculitis including: including Takayasu's arteritis and giant cell 
arteritis/temporal arteritis  
• Medium sized and/or small vessels vasculitis including: polyarteritis nodosa, Kawasaki's disease, microscopic polyangiitis, Wegener's granulomatosis, Churg −Strauss syndrome 
(allergic granulom atous angiitis), Buerger ’s disease (thromboangiitis obliterans), 
necrotizing vasculitis and anti -neutrophil cytoplasmic antibody (ANCA) positive vasculitis 
(type unspecified), Henoch− Schönlein purpura, Behcet's syndrome, leukocytoclastic 
vasculitis  
Moderna Therapeutics , Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3 
 Page 96 Others:  
• Antiphospholipid syndrome 
• Autoimmune hemolytic anemia  
• Autoimmune glomerulonephritis (including IgA nephropathy, glomerulonephritis rapidly 
progressive, membranous glomerulonephritis, membranoproliferative glomerulonephritis, 
and mesangioproliferative glomerulonephritis) 
• Autoimmune myocarditis/cardiomyopathy  
• Autoimmune thrombocytopenia 
• Goodpasture syndrome 
• Idiopathic pulmonary fibrosis 
• Pernicious anemia  
• Raynaud’s phenomenon 
• Sarcoidosis 
• Sjögren ’s syndrome 
• Stevens -Johnson syndrome 
• Uveitis  
Moderna Therapeutics , Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3 
 Page 97 6.3 Appendix 3: Toxicity Grading Scale Tables  
The toxicity grading scales for clinical and laboratory abnormalities are presented in Table  6-3 
and Table  6-4, respectively.  Note that for laboratory abnormalities, grading only occurs if the 
values reside outside of the normal values established by the clinical laboratory. For 
study- specific laboratory normal ranges and associated toxicity grades, refer to the laboratory 
manual.  
Table  6-3 Tables for Clinical Abnormalities  
Local Reaction to Injectable 
Product  Mild  
(Grade 1)  Moderate  
(Grade  2) Severe 
(Grade  3) Potentially 
Life 
Threatening  
(Grade 4)  
Pain  Does not 
interfere with 
activity  Repeated use of 
non-narcotic 
pain reliever 
> 24 hours or 
interferes with 
activity  Any use of 
narcotic pain 
reliever or 
prevents daily 
activit y ER visit or 
hospitalization  
Tenderness  Mild discomfort 
to touch  Discomfort 
with movement  Significant  
discomfort at 
rest ER visit or 
hospitalization  
Erythema/Redness*  2.5 – 5 cm  5.1 – 10 cm  > 10 cm  Necrosis or 
exfoliative 
dermatitis  
Induration/Swelling**  2.5 – 5 cm and 
does not 
interfere with 
activity  5.1 – 10 cm or 
interferes with 
activity  > 10 cm or 
prevents daily 
activity  Necrosis  
Abbreviation: ER, emergency room.  
* In addition to grading the measured local reaction at the greatest single diameter, the measurement should be 
recorded as a continuous variable.  
** Induration/swelling should be evaluated and graded using the functional scale as well as the actual 
measure ment.  
Source: Guidance for industry – Toxicity grading scale for heathy adult and adolescent volunteers enrolled in 
preventative vaccine clinical trials; Tables for clinical abnormalities ( CBER 2007).  
 
Moderna Therapeutics , Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3 
 Page 98 Vital Signs *  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe 
(Grade 3)  Potentially Life 
Threatening  
(Grade 4)  
Tachycardia (beats per 
minute)  101 – 115 116 – 130 > 130  ER visit or 
hospitalization 
for arrhythmia  
Bradycardia (beats per 
minute)**   50 – 54 45 – 49 < 45 ER visit or 
hospitalization 
for arrhythmia  
Hypertension (systolic) (mm  Hg) 141 – 150 151 – 155 > 155  ER visit or 
hospitalization 
for malignant 
hypertension 
Hypertension (diastolic) (mm  Hg) 91 – 95 96 – 100 > 100  ER visit or 
hospitalization 
for malignant 
hypertension 
Hypotension (systolic) (mm  Hg)  85 – 89 80 – 84 < 80 ER visit or 
hospitalization 
for hypotensive 
shock  
Respiratory rate (breaths per minute)  17 – 20 21 – 25 > 25 Intubation  
Abbreviation: ER, emergency room.  
Note that fever is classified under systemic reactions for grading purposes.  
* Subject should be at rest for all vital sign measurements.  
** When resting heart rate is between 60 – 100 beats per minute. Use clinical judgment when characterizing 
bradycardia among some healthy subject populations, for  example, conditioned athletes.  
Source: Guidance for industry – Toxicity grading scale for heathy adult and adolescent volunteers enrolled in 
preventative vaccine clinical trials; Tables for clinical abnormalities ( CBER 2007).  
 
Moderna Therapeutics , Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3 
 Page 99 Systemic (General)  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe 
(Grade 3)  Potentially Life 
Threatening  
(Grade 4)  
Fever (°C) *  
(°F) *  38.0 – 38.4 
100.4 – 101.1  38.5 – 38.9 
101.2 – 102.0  39.0 – 40 
102.1 – 104 > 40 
> 104  
Nausea/vomiting  No interference 
with activity or 1 to 
2 episodes/ 
24 hours  Some interference 
with activity or 
> 2 episodes/ 
24 hours  Prevents daily 
activity, requires 
outpatient IV 
hydration ER visit or 
hospitalization 
for hypotensive 
shock  
Diarrhea  2 – 3 loose stools 
or < 400 g/ 
24 hours  4 – 5 stools or 400 
– 800 g/ 24 hours  6 or more watery 
stools or 
> 800 g/ 
24 hours or 
requires 
outpatient IV 
hydration ER visit or 
hospitalization  
Headache  No interference 
with activity  Repeated use of 
non-narcotic pain 
reliever > 24 hours 
or some 
interference with 
activity  Significant; any 
use of narcotic 
pain reliever or 
prevents daily 
activity  ER visit or 
hospitalization  
Fatigue /Malaise  
(unusual tiredness)  No interference 
with activity  Some interference 
with activity  Significant; 
prevents daily 
activity  ER visit or 
hospitalization  
Generalized myalgia 
(muscle ache or pain)  No interference 
with activity  Some interference 
with activity  Significant; 
prevents daily 
activity  ER visit or 
hospitalization  
Generalized arthralgia 
(joint ache or pain)  No interference 
with activity  Some interference 
with activity not 
requiring medical 
intervention  Prevents daily 
activity and 
requires medical 
intervention  ER visit or 
hospitalization  
Abbreviations: ER, emergency room; IV , intravenous.  
* Oral temperature; no recent hot or cold beverages or smoking.  
Source s: Guidance for industry – Toxicity grading scale for heathy adult and adolescent volunteers enrolled in 
preventative vaccine clinical trials; Tables for clinical abnormalities ( CBER 2007 ), Division of AIDS 
(DAIDS ) Grading the Severity of Adult and Pediatric Adverse Events (DAIDS 20 14). 
Moderna Therapeutics , Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3 
 Page 100 Table  6-4 Tables for Laboratory Abnormalities 
Serum Chemistry*  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe 
(Grade 3)  Potentially Life 
Threatening  
(Grade 4)**  
Sodium – hyponatremia (mEq/L)  132 – 134 130 – 131 125 – 129 < 125  
Sodium – hypernatremia (mEq/L)  144 – 145 146 – 147 148 – 150 > 150  
Potassium – hyperkalemia (mEq/L)  5.1 – 5.2 5.3 – 5.4 5.5 – 5.6 > 5.6  
Potassium – hypokalemia (mEq/L)  3.5 – 3.6 3.3 – 3.4 3.1 – 3.2 < 3.1  
Glucose – hypoglycemia (mg/dL)  65 – 69 55 – 64 45 – 54 < 45 
Glucose – hyperglycemia  
Random (mg/dL)   
110 – 125  
126 – 200  
> 200 Insulin requirements or 
hyperosmolar coma  
Blood urea nitrogen (mg/dL)  23 – 26 27 – 31 > 31 Requires dialysis  
Creatinine (mg/dL)  1.5 – 1.7 1.8 – 2.0 2.1 – 2.5 > 2.5 or requires 
dialysis  
Calcium – hypocalcemia (mg/dL)  8.0 – 8.4 7.5 – 7.9 7.0 – 7.4 < 7.0  
Calcium – hypercalcemia (mg/dL)  10.5 – 11.0 11.1 – 11.5 11.6 – 12.0 > 12.0  
Albumin – hypoalbuminemia 
(g/dL)  2.8 – 3.1 2.5 – 2.7 < 2.5  – 
Total Protein – hypoproteinemia 
(g/dL)  5.5 – 6.0 5.0 – 5.4 < 5.0  – 
Alkaline phosphate; increase by 
factor  1.1 – 2.0 × 
ULN  2.1 – 3.0 × 
ULN  3.1 – 10 × 
ULN  > 10 × ULN 
Liver function tests –ALT and 
AST; increase by factor  1.1 – 2.5 × 
ULN  2.6 – 5.0 × 
ULN  5.1 – 10 × 
ULN  > 10 × ULN 
Bilirubin – when accompanied by 
any increase in liver function test; increase by factor  1.1 – 1.25 × 
ULN  1.26 – 1.5 × 
ULN  1.51 – 1.75 
× ULN  > 1.75 × ULN  
Bilirubin – when liver function test 
is normal; increase by factor  1.1 – 1.5 × 
ULN  1.6 – 2.0 × 
ULN  2.0 – 3.0 × 
ULN  > 3.0 × ULN 
Pancreatic enzymes – amylase and 
lipase  1.1 – 1.5 × 
ULN  1.6 – 2.0 × 
ULN  2.1 – 5.0 × 
ULN  > 5.0 × ULN 
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; ULN, upper limit of the normal 
range.  
* The laboratory values provided in the tables serve as guidelines and are dependent upon institutional normal  
parameters. Institutional normal reference ranges should be provided to demonstrate that they are appropriate.  
** The clinical signs or symptoms associated with laboratory abnormalities might result in characterization of the laboratory abnormalities as p otentially life threatening (Grade 4). For example, a low sodium value that 
falls within a Grade 3 parameter (125 – 129 mE/L) should be recorded as a Grade 4 hyponatremia event if 
the subject had a new seizure associated with the low sodium value.  
Source: Guidance for industry – Toxicity grading scale for heathy adult and adolescent volunteers enrolled in 
preventative vaccine clinical trials; Tables for laboratory abnormalities ( CBER 2007).  
Moderna Therapeutics , Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3 
 Page 101 Hematology *  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe 
(Grade 3)  Potentially Life 
Threatening  
(Grade 4)  
Hemoglobin (female) 
(g/dL)  11.0 – 12.0 9.5 – 10.9 8.0 – 9.4 < 8.0  
Hemoglobin (female) change from Baseline 
value (g/dL)  Any decrease – 
1.5 1.6 – 2.0 2.1 – 5.0 > 5.0  
Hemoglobin (male) 
(g/dL)  12.5 – 13.5 10.5 – 12.4 8.5 – 10.4 < 8.5  
Hemoglobin (male) 
change from Baseline value (g/dL)  Any decrease – 
1.5 1.6 – 2.0 2.1 – 5.0 > 5.0  
WBC increase 
(cell/mm3) 10 800 – 15 000 15 001 – 20 000 20 001 – 25 000 > 25 000 
WBC decrease (cell/mm
3) 2500 – 3500  1500 – 2499  1000 – 1499  < 1000  
Lymphocytes decrease 
(cell/mm3) 750 – 1000  500 – 749 250 – 499 < 250  
Neutrophils decrease (cell/mm
3) 1500 – 2000  1000 – 1499  500 – 999 < 500  
Eosinophils (cell/mm3) 650 – 1500  1501 – 5000  > 5000  Hypereosinophilic  
Platelets decreased 
(cell/mm3) 125 000 – 
140 000 100 000 – 124 000 25 000 – 99 000 < 25 000 
PT; increase by factor  1.0 – 1.10 × ULN  1.11 – 1.20 × ULN  1.21 – 1.25 × ULN  > 1.25 × ULN  
PTT; increase by factor  1.0 – 1.2 × ULN  1.21 – 1.4 × ULN  1.41 – 1.5 × ULN  > 1.5 × ULN 
Abbreviations: PT, prothrombin time; PTT, partial thromboplastin time; ULN, upper limit of normal; WBC, white 
blood cell.  
* The laboratory values provided in the tables serve as guidelines and are dependent upon institutional normal 
parameters. Institutional normal reference ranges should be provided to demonstrate that they are appropriate.  
Source: Guidance for industry – Toxicity grading scale for heathy adult and adolescent volunteers enrolled in 
preventative vaccine clinical trial s; Tables for laboratory abnormalities ( CBER 2007).  
 
Moderna Therapeutics , Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3 
 Page 102 Urine *  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe 
(Grade 3)  Potentially Life 
Threatening  
(Grade 4)  
Protein  Trace  1+ 2+ Hospitalization or 
dialysis  
Glucose  
Trace  1+ 2+ Hospitalization 
for 
hyperglycemia  
Blood (microscopic) – 
red blood cells per high 
power field (rbc/hpf)  1 – 10 11 – 50 > 50 and/or gross 
blood  Hospitalization or 
packed red blood 
cells transfusion  
* The laboratory values provided in the tables serve as guidelines and are dependent upon institutional normal 
parameters. Institutional normal reference ranges should be provided to demonstrate that they are appropriate.  
Source: Guidance for industry – Toxicity grading scale for heathy adult and adolescent vol unteers enrolled in 
preventative vaccine clinical trials; Tables for laboratory abnormalities ( CBER 2007).  
 
Moderna Therapeutics , Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3 
 Page 103 7 Reference List  
Akahata W, Yang ZY , Andersen H, et al. A virus -like particle vaccine for epidemic chikungunya 
virus protects nonhuman primates against infection. Nat Med. 2010;16(3):334-8. 
Brandler S, Ruffie C, Combredet C, et al. A recombinant measles vaccine expressing 
chikungunya virus -like particles is strongly immunogenic and protects mice from lethal 
challenge with chi kungunya virus. Vaccine. 2013;31(36):3718-25. 
Centers for Disease Control and Prevention. Chikungunya virus geographic distribution [updated 22 Apr 2016; cited 2016 Sep 09]. Available from: http://www.cdc.gov/chikungunya/geo/index.html. 
Chang LJ, Dowd KA, Mendoza FH, et al. Safety and tolerability of chikungunya virus -like 
particle vaccine in healthy adults: a phase 1 dose- escalation trial. Lancet.  
2014;384(9959):2046-52. Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyret in 
amyloidosis. N Engl J Med. 2013;369(9):819-29. 
Couderc T, Chretien F, Schilte C, et al. A mouse model for chikungunya: young age and 
inefficient type -I interferon signaling are risk factors for severe disease. PLoS Pathog.  
2008;4(2);e29. 
Couderc T, Khandoudi N, Grandadam M, et al. Prophylaxis and therapy for chikungunya virus 
infection. J Infect Dis. 2009;200(4):516-23. 
Darwin JR, Kenney JL, Weaver, SC. Transmission potential of two chimeric Chikungunya 
vaccine candidates in the urban mosquito vectors, Aedes aegypti and Ae. Albopictus. Am J 
Trop Med Hyg. 2011;85(6):1012-5. 
Department of Health and Human Services, Food and Drug Administration, Center for 
Biologics Evaluation and Research (CBER) (US). Guidance for industry:  Toxicity grading 
scale for healthy adult and adolescent volunteers enrolled in preventative vaccine clinical trials . 
September 2007 [cited 2016 Sep 14] [8 screens]. Available from: 
http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/G uidances/Vaccines/ucm091977.pdf. 
Moderna Therapeutics , Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3 
 Page 104 Division of AIDS  (DAIDS). Table for Grading the S everity of Adult and Pediatric Adverse 
Events Version 2.0. November 2014 [cited 2016 Sep 14] [ 33 screens]. Available from: 
http://rsc.tech -
res.com/document/safetyandpharmacovigilance/daids_ae_grading_table_v2_nov2014.pdf. 
Edelman R, Tacket CO, Wassermann SS, et al. Phase II sa fety and immunogenicity study of 
live chikungunya virus vaccine TSI- GSD-218. Am J Trop Med Hyg. 2000;62(6):681-5. 
Fitzgerald K, Frank -Kamenetsky M, Shulga- Morskaya S, et al. Effect of an RNA interference 
drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the 
concentration of serum LDL cholesterol in healthy volunteers: a randomised, single -blind, 
placebo -controlled, phase 1 trial. Lancet. 2014;383(9911):60-8. 
Gardner C, Burke C, Higgs S, et al. Interferon -alpha/beta deficiency greatly exacerbates 
arthritogenic disease in mice infected with wild -type chikungunya virus but not with the cell 
culture- adapted live- attenuated 181/25 vaccine candidate. Virology. 2012;425:103-12. 
Halstead SB. Reappearance of chikungunya, formerly called dengue, in the Americas. Emerg Infect Dis. 2015;21(4):557-61. 
Hawman D, Stoermer K, Montgomery S, et al. Chronic joint disease caused by persiste nt 
chikungunya virus infection is controlled by the adaptive immune response. J Virol. 
2013;87(24):13878-88. Kam YW, Lum FM, Teo TH, et al. Early neutralizing IgG response to chikungunya virus in 
infected patients targets a dominant linear epitope on the E 2 glycoprotein. EMBO Mol Med. 
2012;4(4):330-43. 
Kam YW, Simarmata D, Chow A, et al. Early appearance of neutralizing immunoglobulin G3 
antibodies is associated with chikungunya virus clearance and long- term clinical protection. J 
Infect Dis. 2012;205(7):1147 -54. 
Kuhn RJ. Togaviridae: The viruses and their replication. In: Knipe DM, Howley PM, editors. Fields Virology. 5th ed. New York: Lippincott Williams & Wilkins; 2007 :1001-22. 
Lanciotti, RS, Kosoy OL, Laven JJ, et al. Chikungunya virus in US travel ers returning from 
India, 2006. Emerg Infect Dis.  2007;13(5):764-7. 
Moderna Therapeutics , Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3 
 Page 105 Li L, Jose J, Xiang Y , et al. Structural changes of envelope proteins during alphavirus fusion. 
Nature. 2010;468(7324):705-8. 
Metz S, Martina B, van den Doel P, et al. Chikungunya virus -like particles are more 
immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits. 
Vaccine. 2013;31(51):6092-6. 
Partidos CD, Weger J, Brewoo J, et al. Probing the attenuation and protective efficacy of a 
candidate chikungunya virus  vaccine in mice with compromised interferon (IFN) signaling. 
Vaccine.  2011;29(16):3067-73. 
Plante K, Rossi S, Bergren NA, at al. Extended preclinical safety, efficacy and stability testing 
of a live -attenuated chikungunya vaccine candidate. ” PLoS Negl Tro p Dis.  2015;9(9):e004007.  
Plante K, Wang E, Partidos CD, et al. Novel chikungunya  vaccine candidate with an 
IRES -based attenuation and host range alteration mechanism. PLos Pathogens.  
2011; 7(7):e1002142. 
Ramsauer K, Schwameis M, Firbas C, et al. Immunogen icity, safety, and tolerability of a 
recombinant measles -virus-based chikungunya vaccine: a randomised, double-blind, placebo-
controlled, active-comparator, first- in-man trial. Lancet Infect Dis. 2015;15(5):519-27. 
Robinson, MC. An epidemic of virus disease in southern province, Tanganyika territory, in 
1952-1953 I: Clinical features. Trans R Soc Trop Med Hyg. 1955;49:28-32.  
Roy C, Adams A, Wang E, et al. (2014). “ Chikungunya vaccine candidate is highly attenuated 
and protects nonhuman primates against tel emetrically monitored disease following a single 
dose. J Infec t Dis.  2014;209(12):1891-99. 
Schwartz, O and Albert ML. Biology and pathogenesis of chikungunya virus. Nat Rev 
Microbiol. 2010;8(7):491-500. Smith SA, Silva LA, Fox JM, et al. Isolation and characterization of broad and ultrapotent 
human monoclonal antibodies with therapeutic activity against chikungunya virus. Cell Host 
Microbe.  2015;18:86-95. 
Moderna Therapeutics , Inc. VAL -181388  
Protocol V AL -181388- P101 Clinical Study Protocol Amendment 3 
 Page 106 Strauss JH and Strauss EG. The alphaviruses: gene expression, replication, and evolution. 
Microbiological Rev.  1994;58(3):491-562. 
Szebeni J. Complement activation -related pseudoallergy: a stress reaction in blood triggered 
by nanomedicines and biologicals. Mol Immunol. 2014;61(2):163-73. 
Tsetsarkin KA, Chen R, Sherman MB, et al. Chikungunya virus: evolution and genetic 
determinants of emergence. Curr Opin Virol. 2011;1(4):310-7.  
van der Broek M, Muller U, Huang S, et al. Antiviral defense in mice lacking both alpha/beta 
and gamma interferon receptors. J Virol.  1995;69(8):4792-6.  
Wang E, V olkova E, Adams A, et al. Chimeric alphavirus vaccine candidates for chikungunya. 
Vaccine.  2008;26(39):5030-9.  
Weaver SC and Lecuit M. Chikungunya virus infections. N Engl J Med. 2015;373(1):94 -5. 
Weaver SC, Osorio JE, Livengood JA, et al. Chikungunya virus and prospects for a vaccine. 
Expert Rev Vaccines.  2012; 11(9):1087-101. 
Zhang R, Hryc CF, Cong Y , et al. 4.4 A cryo- EM structure of an enveloped alphavirus 
Venezuelan equine encephalitis virus. EMBO. 2011;30(18):3854-63. 
 